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Mixed Lineage Leukaemia 5 (MLL5) is a mammalian Trithorax group (TrxG) gene 
located at chromosome band 7q22, a frequently deleted region in myeloid 
malignancies. MLL5 was discovered and subsequently cloned in year 2002. Currently, 
there are a total of fifteen publications dedicated to MLL5.  
 
MLL5 is identified as a nuclear protein and either over-expression or depletion of 
MLL5 resulted in dual-phase cell cycle arrest. In interphase cells, MLL5 exhibits 
distinct irregular, punctate intra-nuclear speckles but with uncharacterized biological 
functions. Intrigued by the complexities of nuclear speckles, which are dynamic 
structures enriched with a reservoir of factors that participate in transcription and pre-
mRNA processing, we attempted to unravel the biological functions of MLL5 within 
the nuclear speckles. To begin with, we examined the co-staining pattern of MLL5 
with several well-characterized proteins that were known to display nuclear speckle 
pattern by immunofluorescence staining. Interestingly, we found that MLL5 nuclear 
speckles exhibited extensive co-localization with the spliceosome protein SC35 which 
has recently been reported to be involved in the bi-directional coupling of 
transcription and splicing. Given the fact that alterations in MLL5 level through 
ectopic over-expression or siRNA-mediated knockdown resulted in the enlargement 
and aggregation of nuclear speckles, a phenotype that indicated a defect in co-
transcriptional splicing process, we therefore speculate a novel biological role of 
MLL5 involving in the transcription and splicing processes. We tested this hypothesis 
by examining if MLL5 is sensitive to transcription inhibitors and whether MLL5 is 
associated with RNA Polymerase II (RNAPII) transcription machinery. Results 
12 
 
showed that MLL5 not only physically interacted with RNAPII but also affected the 
progression of RNAPII along the DNA template as MLL5 depletion resulted in 
chromatin compaction and affected the subunits of chromatin remodelling proteins. In 
addition, histone signatures signifying transcription activation, namely H3K4 tri-
methylation and H4 acetylation, were largely reduced in MLL5-kockdown cells. 
Splicing activity was also reduced as a result of a disruption in the transcription 
process. Taken together, our findings suggest that MLL5 participates in transcription 




















CHAPTER 1 – INTRODUCTION 
 
1.1 Nuclear speckles 
 
1.1.1 Discovery of nuclear speckles 
 
The pioneer work for nuclear speckles was reported by Santiago Ramo n´ y Cajal in 
1910 [reviewed in (Lafarga et al., 2009)]. In this study, Ramo n´ used acid aniline 
stains to identify structures he described as “grumos hialinas”, which literally meant 
“translucent clumps”. In 1959, through the use of electron microscopy, Hewson Swift 
(Swift, 1959) observed particles in the cells to be localized in “clouds” instead of 
being randomly distributed. Further investigations by Swfit through cyto-chemical 
analysis suggested that these particles harboured ribonucleic acid (RNA). Swift 
termed these particles as interchromatin particles. It was only in 1961 when researcher 
J. Swason Beck (Beck, 1961), upon examining rat liver sections that were immune-
labelled with serum from auto-immune disorder patients, coined the term “speckles” 
for the interchromatin particles that were discovered two years ago. However, it was 
only after several years later that the first connection between pre-mRNA splicing and 
nuclear speckles or interchromatin granules emerged. This was found through an 
examination of the distribution of small nuclear ribonucleoproteins (snRNP antigens) 
using anti-splicing factor-specific antibodies that illustrated a speckled distribution of 
snRNPs in the cell nuclei (Perraud et al., 1979; Lerner et al., 1981; Spector et al., 
1983). These distinct classes of sub-nuclear bodies have always been an area of 
intense research even till present.  
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1.1.2 Characterization and dynamics of nuclear speckles 
 
The mammalian cell nucleus is a multi-functional and complex organelle where a 
plethora of cellular mechanisms occur in sub-nuclear compartments collectively 
termed as foci. These foci, approximately 20-50 of them diffusely distributed in the 
nucleoplasm, appeared as irregular, punctate structures with interconnections existing 
in variable shapes and sizes (Lamond and Spector, 2003). These distinct foci, 
identified as nuclear speckles and Cajal (coiled) bodies, are dynamic structures 
involved in transcription and pre-mRNA splicing (Spector, 1993; Matera, 1999). 
Further characterizations by electron microscopy revealed these nuclear speckles to 
co-localize in nuclear regions designated as interchromatin granules clusters (IGCs) 
and perichromatin fibres (PFs) (Fakan et al., 1984; Raska et al., 1990; Spector et al., 
1993). Active pre-mRNA transcription pre-dominates at the PFs that are enriched 
with nascent DNA, RNA, RNA polymerase II (RNAPII) and histone modifiers for 
transcriptionally active chromatin. Splicing speckles observed in IGCs signifed the 
sites for splicing factor assembly and storage as well as the sites for splicing processes 
such as RNA editing and transport (Carter et al., 1991; Wang et al., 1991; Spector and 
Lamond, 2011).  
 
Nuclear speckles are dynamic structures and there is a continuous shuttling of splicing 
factors in and out of the speckles. In the event of transcription inhibition, either 
through the use of inhibitors or as a consequence of heat-shock, nuclear speckles 
became enlarged and rounded as splicing factors aggregate in them (Spector et al., 
1991; Melcak et al., 2000). However, when the expression of intron-containing genes 
is high (Huang and Spector, 1996; Misteli et al., 1997) or during a viral infection 
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when transcription activity increases (Jimenez-Garcia and Spector, 1993; Bridge et al., 
1995), the accumulation of splicing factors within the speckles decrease as they get 
distributed to the transcription sites in the nucleoplasm. Undeniably, much progress 
has been made in recent years towards a better understanding of the structure and 
function of the nuclear speckles. However, given the dynamic nature of the speckle 
morphology, answers to a number of questions remain. In particular, the detailed 
molecular mechanism on how the components of the nuclear speckles efficiently 
coordinate the complex events in the cell, how splicing factors systematically execute 





1.2.1 An overview  
 
Nuclear pre-mRNA splicing is an essential and important process that governs 
eukaryotic gene expression. It is a process where introns are excised and this occurs in 
the spliceosome complexes that constitute two different classes of snRNP antigens - 
U1, U2, U4/U6, U5 (Bindereif and Green, 1990) and non-snRNP antigens like SC35 
(Reed, 1990). Both groups belong to the serine/arginine (SR) family and share 
structural features including an RNA binding domain and a SR-rich domain that is 
responsible for their targeting to nuclear speckles (Zahler et al., 1992; Birney et al., 
1993). These proteins function cooperatively to catalyse the excision of the 




Among the SR protein family, SC35, discovered through a monoclonal antibody 
against partially purified spliceosomes, is commonly used to define splicing nuclear 
speckles (Fu and Maniatis, 1990). The group discovered that SC35 co-localized well 
with snRNPs within the speckled nuclear domains, thereby providing the first 
evidence that these speckled regions constituted both types of snRNPs. It has been 
reported that nuclear extracts depleted of SC35 was incapable of splicing exogenous 
pre-mRNA. However, this was a reversible process as splicing activity could be 
restored by complementing the extracts with SC35 antigen or other members of the 
SR family (Zahler et al., 1992).   
 
The process of pre-mRNA splicing constituted two trans-esterification reactions, 
namely lariat intron formation and exon ligation. Briefly, this occurred in an orderly 
step-wise manner, involving the interaction between the spliceosomal snRNPs and 
non-snRNPs such as splicing factors SC35. Briefly, U1-snRNP first associated with 
the 5' splice site, thereafter, the attachment of the U2-snRNP near the branch-point 
enable the entry of the U4/U5/U6 tri-snRNP complex to complete the spliceosome 
assembly. Structural rearrangements then occurred and this resulted in U1 and U4 
expulsion, catalytic activation, lariat formation, exon ligation, spliced product release 
and the eventual association of the remaining components that constitute the 
spliceosome assembly. A simplified representation of the spliceosome assembly 
pathway and pre-mRNA splicing is illustrated in Figure 1. Over the years, extensive 
research has revealed that the splicing of pre-mRNA in eukaryotes is also tightly 
coupled to the transcription process and this occurs as nascent transcripts are 
synthesized from RNA polymerase II. In fact, unravelling the splicing process not 
only aid in having a better understanding of gene expression at the molecular level; 
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even at the medical level, it allows for better treatment and prognosis as aberrant pre-








Figure 1: A simplified representation of the spliceosome assembly pathway and 
pre-mRNA splicing. The pre-mRNA is depicted with rectangular boxes (blue) as 
exons, linked by a single intron (black line) from the 5’to the 3’ splice sites (SS). For 
simplicity, only the ordered interactions of the snRNPs (indicated by circles), but not 
those of non-snRNP proteins are illustrated. During the assembly phase, the 
spliceosomal snRNP U1 first assembles onto the pre-mRNA before the systematic 
recruitment of U2, followed by the other snRNPs. During activation, the Prp28-
associated complex joins the spliceosome while the U1 and U4 snRNPs depart. 
Catalysis proceeds in two steps: lariat formation and exon ligation. Eventually, the 
mRNA is released and the spliceosome is disassembled. Backward arrows indicate the 







1.3 Transcription  
 
1.3.1 An overview  
 
RNA polymerase II (RNAPII) is a key player in the transcription process. Prior to 
splicing, nascent RNA transcripts are generated by RNAPII. The RNAPII harbours 52 
tandem consensus heptapeptide (YSPTSPS) repeats at its C-terminal domain 
(RNAPII CTD)  (Corden, 1990) and phosphorylation on the multi-sites controls the 
state of transcription. RNAPII with un-phosphorylated CTD is recruited to the pre-
initiation site at the promoters while the transition between transcription initiation and 
elongation is mediated by multi-phosphorylation events that are catalysed by protein-
kinase complexes. Cdk7-cyclinH phosphorylates RNAPII CTD at Serine-5, 
generating a hypo-phosphorylated RNAPII (RNAPIIa) that participates in 
transcriptional initiation. Phosphorylation at Serine-2 is catalysed by Cdk9-cyclinT, 
forming hyper-phosphorylated RNAPII (RNAPIIo) that associates with 
transcriptional elongation (Zawel et al., 1995).  RNAPIIo has also been reported to 
exist in splicing factor-rich nuclear speckles (Bregman et al., 1995; Mortillaro et al., 
1996) and significant enrichment and co-localization has been observed for Cyclin T1 
with the nuclear speckles than Cdk9 (Herrmann and Mancini, 2001). A growing body 
of evidence has also suggested that Cdk9 not only regulates RNAPII activity, but also 
participates in co-transcriptional histone modifications and pre-mRNA processing like 






1.3.2 Coordination between transcription and splicing 
 
Emerging evidence has proved that functional integration of transcription by RNAPII 
and RNA processing machineries are mutually beneficial for efficient and regulated 
gene expression. The transcription process progresses from the initiation phase to the 
elongation phase and finally, the termination phase and these coordinated events 
within the cell nucleus are briefly summarized in Figure 2. Research over the years 
has also suggested that RNAPII CTD is critical in coupling the transcription and 
splicing processes as several observations have associated the elongating RNAPII to 
pre-mRNA splicing (Corden and Patturajan, 1997; Bentley, 1999; Hirose and Manley, 
2000). Phosphorylated CTD serves as a recruitment and docking site for mRNA 
processing factors (Greenleaf, 1993) and stimulates the early steps of spliceosome 
assembly (Hirose et al., 1999). Besides, the phosphorylated CTD also recruits 
chromatin modifiers such as histone methyltransferases Set 1/2 (Phatnani and 
Greenleaf, 2006; Yoh et al., 2008) and histone acetyltransferases p300 and PCAF 
(p300/CBP-associated factor) (Cho et al., 1998). Hence, the cycle of phosphorylation 
and de-phosphorylation at the CTD during each round of transcription may coordinate 





Figure 2: Integration of transcription and pre-mRNA processing. RNAPII is 
modified on its CTD with Serine-5 phosphorylation predominately at the start of the 
gene (blue line) and Serine-2 phosphorylation in the middle and end of the gene 
(yellow line). 5’-Capping enzymes are recruited through direct interactions with 
Serine-5 phosphorylated CTD to catalyse the co-transcriptional capping reaction. 
Various splicing factors are recruited during the elongation phase of transcription to 
facilitate co-transcriptional splicing. These splicing factors are dependent on Serine-2 
phosphorylation on the CTD. The 3’-end formation is functionally coupled to 
transcription termination. Importantly, increasing evidence now suggests that the 
transcription and RNA processing machineries are functionally integrated in a 
reciprocal fashion such that individual co-transcriptional processing events can 




Recently, Lin and colleagues (Caslini et al., 2009) has uncovered a new and important 
role in transcription for a splicing regulator protein, SC35, that has previously been 
thought to be involved primarily in the splicing process. In the study, SC35 is needed 
to promote RNAPII elongation in a subset of genes where depletion in SC35 
dramatically caused a decrease in nascent RNA synthesized by RNAPII but has no 
effect on the transcription by RNA polymerase I. Through the use of chromatin 
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immunoprecipitation combined with microarrays (ChIP-chip), the group observed that 
RNAPII was accumulated within the gene body upon SC35 depletion, indicating 
RNAPII stalling before it reached the end of the gene. This stalling led to a decrease 
in RNAPII elongation, which was confirmed by measuring the nascent transcripts 
using a run-on assay that utilized non-radioactive nucleotides. In short, these findings 
confirm the involvement of SC35 in the bi-directional coupling between transcription 




Figure 3: Bi-directional coupling: a splicing factor regulates transcription, which 
in turn regulates alternative splicing. The splicing factor SC35 interacts with RNA 
polymerase II (Pol II) and the elongation factor P-TEFb and, via phosphorylation of 
the C-terminal domain (CTD) of Pol II at Serine2 (Ser2), stimulates transcriptional 
elongation. In parallel, high elongation rates allow the simultaneous presentation to 
the splicing machinery of strong and suboptimal 3’ splice sites, which favours the use 
of the stronger one, leading to skipping of an alternative exon. [Adapted from (Fededa 




In summary, the continuous shuttling of splicing factors to active transcription sites 
brings the elongating and splicing complexes into close proximity to facilitate co-
transcriptional splicing. Given the tight coupling of transcription with the downstream 
RNA processing steps, transcription inhibition may halt a chain of gene expression 
events and arrest complexes at various RNA metabolism stages. Such disruption in 
transcription activity causes nuclear speckles to accumulate in the cell nucleus in an 
aggregate manner.   
 
 
1.3.3 Chromatin organization and transcription  
 
Extensive chromatin research over the years indicates that chromatin structure is a 
primary regulator of gene transcription. The dynamics of chromatin structure is tightly 
regulated through multiple mechanisms which include histone modifications, 
chromatin remodelling, histone variant incorporation and histone eviction. In this 
study, we will examine how histone modifications and chromatin remodelling affect 
transcription. 
 
Histone tails are susceptible to numerous post-translational modifications (Li et al., 
2007). These modifications include methylation of arginine (R) residues; methylation, 
acetylation, ubiquitination, ADP-ribosylation, and sumoylation of lysines (K); and 
phosphorylation of serines and threonines. Among them, modifications pertaining to 
active transcription include acetylation of histone 3 and histone 4 (H3 and H4) or di- 
or tri-methylation of H3K4; and these are classified as euchromatin modifications. 
Heterochromatin modifications are associated with inactive transcription, and 
methylation occurs on H3K9 or H3K27. These histone modifications consequently 
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cause a change in the net charge of the nucleosomes, which in turn could strengthen 
or weaken inter-or intranucleosomal DNA-histone interactions. These effects 
eventually affect RNAPII progression along the chromatin, thereby affecting 
transcription.  
 
Chromatin remodelling is an energy-dependent process which involves a transient 
unwrapping of DNA from histone octamers. This facilitates transcription factors to 
become accessible to nucleosomal DNA. An example of chromatin modellers are the 
SWItch/Sucrose Non-Fermentable (SWI/SNF) proteins, which are a group of highly 
conserved DNA-stimulated ATPase complex (Muchardt and Yaniv, 1999). Taken 
together, chromatin architecture and its dynamic nature has a crucial role in dictating 
the fate of DNA-related metabolic processes which include DNA 
repair/recombination/replication, in particular, transcription by RNAPII that will be 
highlighted in this thesis.   
 
1.4 Mixed Lineage Leukemia (MLL) Protein Family 
 
1.4.1 A summary of MLL protein family  
 
The mammalian mixed lineage leukemia (MLL) family comprises five members 
(MLL1, MLL2, MLL3, MLL4/ALR and MLL5) and these proteins are human 
homologues of the Drosophila Trithorax group (TrxG) gene. Vertebrate and 
Drosophila TrxG genes encode transcriptional regulators that are postulated to be 
involved in the maintenance of gene expression. Proteins that are encoded by TrxG 
repress Homeobox (HOX) gene expression while their other antagonistic parties, 
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polycomb group (PcG) proteins, maintain the HOX gene expression (Ziemin-van der 
Poel et al., 1991). The mechanisms by which these two evolutionally conserved genes 
maintain the HOX gene expressions occur at the epigenetic level by chromatin 
remodeling and histone modifications, upon the formation of multi-protein complexes 
(Muller et al., 2002; Schuettengruber et al., 2007). Since HOX gene expressions are 
essential in determining the fates of embryonic development and haematopoiesis, 
aberrant HOX gene expression may represent a major molecular consequence of 
leukaemia-associated genetic lesions (Orlando and Paro, 1995; Look, 1997; Dorrance 
et al., 2006) 
 
MLL protein family possesses variable number of cysteine-rich plant homeodomain 
(PHD), zinc fingers and a highly-conserved Su(var)3-9, enhancer-of-zeste and 
trithorax (SET) domain. A schematic representation of MLL protein family is 
illustrated in Figure 4. Structural and biochemical analysis show that PHD finger and 
SET domain are involved in protein-protein interactions (Gould, 1997; van Lohuizen, 
1999). PHD finger is usually present in chromatin-associated proteins and has been 
reported to be associated with nucleosomes or specific nuclear protein partners 
(Aasland et al., 1995) or serve as binding or recognition modules for histone 
modifications (Mellor, 2006) while the SET domain possesses methyltransferase 
activity (Nakamura, et al. 2002). Among the MLL family, MLL1 is the most 
extensively studied. For instance, the existence of PHD fingers within MLL1 regulate 
homodimerization and are indispensable for the interaction with cyclophilin Cyp33 







Figure 4: A schematic presentation of MLL family proteins. In comparison with 
other family members, MLL5 has a sole PHD finger and a centralized SET domain. 
The graph is constructed base on the domain analysis results from SMART 
(http://smart.embl-heidelberg.de/). The evolutionary relationship among the family 
members is drawn using cladogram from ClustalW 





1.4.2 MLL protein family as human H3K4 specific methyltransferases 
 
 In human, there are at least eight H3K4-specific histone methyltransferases (HMTs) 
which include MLL protein family (MLL1, MLL2, MLL3, MLL4, MLL5, hSet1A, 
hSet1B and ASH1) (Dou et al., 2006). Members of the MLL protein family are the 
main epigenetic regulators of diverse gene types that are associated with cell-cycle 
regulation, embryogenesis and development.  
 
Within the MLL family, MLL1 is located on the human chromosome band 11q23 and 
has been the most extensively studied (Djabali et al., 1992; Gu et al., 1992). A study 
by Poet and colleagues (Ziemin-van der Poel et al., 1991) revealed that MLL1 is 
associated with chromosome translocations in myeloid and lymphoid leukemia. 
Similarly, Djabali and colleagues (Djabali et al., 1992) found that the recurring 
translocations on MLL1 resulted in infant and therapy-related leukemias. Closely 
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homologous to MLL1 is MLL2 where both share the same interacting partners (Liu et 
al., 2009). Findings by Hughes and Yokoyama groups (Hughes et al., 2004; 
Yokoyama et al., 2004) showed that both MLL1 and MLL2 formed H3K4 histone 
methyltransferase complexes that constituted WD Repeat Domain 5 (WDR5), 
Retinoblastoma Binding protein 5 (RbBP5) and Absent, Small or Homeotic-like 
(Drosophila) (ASH2L). In another study, human CpG-binding protein (CGBP) was 
found to interact with MLL1, MLL2 and human Set1, and was a core component of 
the HMT complexes (Ansari et al., 2008). Dou and colleagues (Dou et al., 2006) have 
successfully purified MLL1 complex that contained histone acetyl transferase, MOF 
and host cell factors (HCF1 and HCF2). On the other hand, MLL3 and MLL4 existed 
in ASC-2-containing co-activator complexes (ASCOM) (Goo et al., 2003; Lee et al., 
2006) with their histone lysine methyltransferase activities often coupled to H3 
acetylation and H3K27 demethylation (Lee et al., 2007; Nightingale et al., 2007).  
These independent studies suggested that MLL-associated HMT activity appeared to 
be functional only when they existed as multi-protein complexes and each MLL-
interacting complex played a distinct role in regulating MLL-mediated histone 
methylation and gene activation. 
 
1.4.3 MLL protein family and transcription 
 
Even though the members of MLL family are commonly associated with regulating 
the HOX genes and H3K4 methylation, recent studies have showed that MLL protein 
family participate in regulating the transcription of diverse gene types (Milne et al., 
2005; Takeda et al., 2006; Caslini et al., 2009; Kim et al., 2009). In the work by 
Guenther and colleagues (Guenther et al., 2005) using a genome-wide promoter 
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binding assay, MLL1 and H3K4 tri-methylation was found to be enriched at the 
promoters of transcriptionally active genes, suggesting MLL1 as a positive global 
regulator of gene transcription. The group also discovered that MLL1 localized to 
microRNA (miRNA) loci that were associated with leukemia and haematopoiesis. 





), Scharf and colleagues (Scharf et al., 2007) demonstrated that Mll1 
was associated with both transcriptionally active and repressed genes. MLL1 was 
found to regulate other gene types that were involved in differentiation and 
organogenesis pathways (such as COL6A3, DCoH, gremlin, GDID4, GATA-6 and 
LIMK) and tumor suppressor proteins involved in cell cycle regulation (p27kip1 and 
GAS-1). MLL1 was also found to be associated with the gene expressions that were 
linked with leukemogenesis and other malignant transformations including HNF-3 ⁄ 
BF-1, Mlf1, FBJ, Tenascin C, PE31 ⁄TALLA-1 and tumor protein D52-like gene 
(Scharf et al., 2007).  
 
On the other hand, MLL3 and MLL4 functioned as a p53 co-activator and were 
needed for H3K4 tri-methylation and expression of endogenous p53 target genes, in 
the presence of the DNA-damaging agent, doxorubicin (Kim et al., 2009). The 
expression of p21, a downstream target gene of p53, was found to be significantly 
decreased in Mll3 deficient mice as compared to the wild-type mice. Even though the 
direct interaction of MLL3 and MLL4 with p53 resulted in transcription activation in 
vitro (Dou et al., 2005), both required the protein, Menin, that acted as a mediator 
before they could be successfully recruited to the promoter of p27 and p18 genes to 
regulate their gene expressions (Milne et al., 2005). Recently, it has also been 
reported that MLL1 depletion led to p53-dependent growth arrest (Caslini et al., 2009).  
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Recent findings have demonstrated MLL1 to be linked with the telomeres. MLL1 was 
reported to affect H3K4 methylation and transcription of telomere in a length-
dependent manner (Caslini et al., 2009). Studies showed that the depletion of MLL1 
by RNA interference in human diploid fibroblasts caused telomere chromatin 
modification, telomere transcription and telomere capping, leading to the telomere 
damage response. In short, these observations suggested the diversified roles of MLL 
protein family in gene regulation apart from being a master regulator of the HOX gene.  
 
1.4.4 MLL protein family and pre-mRNA processing  
 
Besides regulating the HOX genes, recent studies have suggested that MLL1 to MLL4 
are involved in coordinating the transcription and splicing processes. ASC2 (a 
component of the ASCOM complex that contains MLL1 to MLL4) exhibited target 
gene specificity to MLL complexes and interacted with CoAA  (a hnRNP-like protein) 
and CAPER, both of which were key components involved in the alternate splicing 
process (Auboeuf et al., 2005). In addition, MLL histone methylases, in particular, 
MLL2, MLL3 and MLL4, have been demonstrated to interact with nuclear receptor 
through critical involvement of ASCOM complex that interacted with players 
participating in alternative splicing. Besides, MLL complexes have also been reported 
to coordinate Ski-complex that was also an important component in mRNA splicing 
(Zhu et al., 2005). Even though these studies showed that MLL1 to MLL4 interacted 
either directly or indirectly with mRNA processing factors, the functional details of 





1.5 Mixed Lineage Leukemia 5 (MLL5) 
 
1.5.1 A summary of MLL5 
 
MLL5 gene was discovered in a search for candidate myeloid leukemia tumour 
suppressor genes from an estimated 2.5 Mb commonly deleted segment within 
chromosome band 7q22 (Emerling et al., 2002). MLL5 is the most recent identified 
member of the human Trithorax (Trx) family and comprises 1858 amino acids. MLL5 
contains 25 exons and spans 73 kb of genomic DNA. It is homologous to Drosophilia 
CG9007 and is evolutionarily more distant to the other family member as shown in 
Figure 4 (Emerling et al., 2002). MLL5 is distantly related to the other family 
members evolutionally as it encodes only a single PHD domain instead of a cluster 
found in other members, with the SET domain located nearer to the N-terminal region 
of the protein. Recent studies have suggested that human MLL5 and mouse MLL5, as 
well as the murine paralog, Setd5, possess SET domains that have sequence 
homology to yeast SET3 and SET proteins (Glaser et al., 2006; Sun et al., 2008). In 
addition, it has also been suggested that MLL5 may be the functional homolog of the 
Saccharomyces cerevisiae SET3; MLL5 was discovered to be a component of the 
NCOR complex, which is postulated to be functionally similar to the SET3C complex 
(Lanz et al., 2006). In addition, unlike the other MLL family proteins, MLL5 lacks 
DNA binding motifs such as A-T hooks and the methyltransferase homology motifs, 
suggesting that MLL5 might not bind DNA but would instead modulate transcription 
indirectly via protein-protein interactions through the PHD and SET domains 




1.5.2 Current findings on MLL5 
 
1.5.2.1 MLL5 and cell cycle regulation 
 
It has been shown that ectopic over-expression of MLL5 inhibits cell cycle 
progression at G1 phase, a crucial DNA damage checkpoint that governs genomic 
stability (Deng et al., 2004). In addition, silencing of MLL5 gene expression by small 
interfering RNAs (siRNAs) retarded cell growth and reversibly arrested cells in G1 
and G2/M phases (Cheng et al., 2008), possibly through the up-regulation of Cyclin 
Dependent Kinase (CDK) inhibitor p21 and the de-phosphorylation of the 
retinoblastoma protein (pRb). Upon MLL5 knockdown, the entry of quiescent 
myoblasts into S-phase was delayed, but the completion of S-phase progression was 
hastened (Sebastian et al., 2009). Genome-based RNA interference profiling in cell 
division has also revealed that MLL5 might function in cytokinesis and mitosis 
(Kittler et al., 2007). Recently, it has been demonstrated that the phosphorylation of 
MLL5 by mitotic kinase Cdc2 is crucial for mitotic entry (Liu et al., 2010). These 
findings suggest that MLL5 has different regulatory roles throughout cell cycle.   
 
1.5.2.2 MLL5 and DNA damage response 
 
Apart from having a regulatory role in cell cycle progression, MLL5 has recently been 
shown to be involved in the DNA damage responses. MLL5 is involved in the 
camptothecin (CPT)-induced p53 activation (Cheng et al., 2011). The treatment of 
actively replicating cells with CPT led to the degradation of MLL5 protein in a time- 
and dose-dependent manner. The down-regulation of MLL5 resulted in the 
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phosphorylation of p53 at Ser392, which was abrogated by exogenous overexpression 
of MLL5. In MLL5-knockdown cells, p53 protein was stabilized and bound to DNA 
with higher affinity, consequently resulting in the activation of downstream genes. In 
short, MLL5 functions as a novel component in the regulation of p53 homeostasis and 
a new cellular determinant of CPT.  
 
1.5.2.3 MLL5 and animal studies 
 
Recently, three independent studies, reporting the first genetic analysis of Mll5 
deficiency in mice have been published (Heuser et al., 2009; Madan et al., 2009; 
Zhang et al., 2009).  Zhang and colleagues created the mice by deleting exon 3 and 4 




 mice displayed postnatal lethality, retarded growth 
and a decrease of long-term hematopoietic stem cells (LT-HSC). However, these mice 
did not show an increase incidence of spontaneous tumours and no cell cycle defects 
in the stem cell compartments were detected. Madan and colleagues embarked a 
similar strategy and observed male sterility in addition to the observations made by 
Zhang’s group. Surviving Mll5-/- mice had reduced thymus, spleen and lymph node 
sizes. Unlike Zhang’s observations, Madan highlighted that Mll5 was needed to 





by disrupting exon 3. It was found that apart from similar observations made by the 




 mice as a 
consequence of defects in neutrophils maturation. Just like Zhang’s group, no mice 
developed spontaneous tumour growth. Recently, Yap and his colleagues 
demonstrated the consequences of MLL5 deficiency in the area of spermatogenesis 
and found that MLL5 has an important role in this process (Yap et al., 2011). Mll5 
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deficient mice experienced defects in terminal maturation and in the packaging of 
sperm. In addition, these sperm were observed to have malfunctions in their motility. 




mice displayed postnatal lethality and retarded growth. In summary, these studies 
revealed that Mll5 plays a pivotal role in hematopoietic stem cell fitness and 
spermatogenesis but is dispensable for embryonic development.  
 
1.5.2.4 MLL5 and epigenetic regulation   
 
By virtue of the SET domain, MLL1 to MLL4 possess Histone H3 Lysine 4 (H3K4)-
specific methyltransferase activity and play vital roles in gene activations and 
epigenetics. (Kuzin et al., 1994; Curradi et al., 2002). Therefore, there is a possibility 
that MLL5 may also possess intrinsic histone methyltransferase activity to regulate 
gene expression through chromatin remodelling. However, several reports suggested 
that MLL5 lacked such intrinsic methyltransferase activity (Nightingale et al., 2007; 
Madan et al., 2009). Sebastian and colleagues (Sebastian et al., 2009) demonstrated 
that although MLL5 lacks inherent histone methyltransferase activity, it is able to 
regulate the expression of histone modifying enzymes Lysine Specific Demethylase 1 
(LSD1) and SET7/9 through an indirect mechanism. MLL5 has also be shown to 
induce quiescent myoblasts to regulate both cell cycle and differentiation through a 
hierarchy of chromatin and transcriptional regulators (Sebastian et al., 2009), 
suggesting that MLL5 may play an essential role in the novel chromatin regulatory 
mechanism. To date, it remains debatable if MLL5 possesses histone H3K4 
methyltransferase (HKMT) activity. Nonetheless, a short N-terminal MLL5 isoform, 
MLL5α (609 amino acids), containing both PHD and SET domains was recently 
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found to act as a mono- and di-methyltransferase to H3K4 only after MLL5 has been 
glcNAcylated (Fujiki et al., 2009). This isoform was identified as part of a multi-
subunit complex, in association with nuclear retinoic acid receptor RARα and also 
facilitates retinoic acid-induced granulopoiesis. Another short N-terminal MLL5 
isoform, MLL5β (503 amino acids), was found to have a critical role in activating 
E6/E7 gene transcription in HPV16/18-induced cervical through its interaction with 
transcription factor AP1 where AP1 binding site is located at the distal region of the 
HPV18 long control region (Yew et al., 2011). Interestingly, a recent report 
demonstrated the prognostic importance and the therapeutic potential of MLL5 in 
acute myeloid leukemia where high MLL5 expression is associated with high overall 
survival and relapse-free survival (Damm et al., 2011). In short, these findings have 
highlighted the multi-functional roles of MLL5 but the molecular details remain 
elusive.  
 
1.6 Aims and objectives of the study 
 
To date, very little information is known about the specific interactions of MLL5 with 
the cellular machineries. The spatial organization of endogenous MLL5 in the cell has 
not been comprehensively elucidated. Functional characterisation by Deng et al 
(Deng et al., 2004) demonstrated that the MLL5 protein has at least three nuclear 
localisation signals and exhibited a speckled nuclear distribution with uncharacterized 
biological functions. The aim of my project is to delineate the functional significance 
of these MLL5 nuclear speckles. Our group has previously shown that the 
phosphorylation and cellular localization of MLL5 is cell-cycle dependent (Cheng et 
al., 2008; Liu et al., 2010). At interphase, MLL5 exhibited distinct intra-nuclear foci 
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(Deng et al., 2004). Phosphorylation by mitotic kinase Cdk1 resulted in the 
dissociation of MLL5 from condensed chromosome, causing the nuclear speckles to 
dissolve (Liu et al., 2010). When cells re-entered G1 cell phase, the intra-nuclear foci 
re-appeared. Since MLL5 participates in cell cycle regulation, we hypothesize that 
these dynamic and cell cycle-specific nuclear speckles may represent functional 
compartmentalization of nuclear processes such as DNA replication/repair, 
transcription or splicing.  
 
To begin with, I examined the co-staining pattern of MLL5 with several well-
characterized proteins that were known to display nuclear speckle pattern by 
immunofluorescence staining and found that MLL5 co-localized with the splicing 
components, SC35 and the snRNP antigens. An alteration in the basal level of MLL5 
resulted in an enlargement of nuclear speckle, a phenotype that is associated with pre-
mRNA splicing or transcription inhibition. These observations suggest the role of 
MLL5 in the transcription or splicing process. Given the close interplay between the 
transcription and splicing processes, the effects of changes in MLL5 expression level 
on transcription and splicing were examined. MLL5 formed aggregates and localized 
in enlarged nuclear speckles in respond to various transcription inhibitors. Br-UTP 
incorporation study revealed a drastic loss in transcription activity in both over-
expression of MLL5 and MLL5-siRNA treated cells. Biochemical analyses 
demonstrated that MLL5 interacted with the transcription machinery complex, RNA 
polymerase II. MLL5 depletion resulted in chromatin compaction and affected the 
subunits of chromatin remodelling proteins. Collectively, these results suggest a novel 
cellular role of MLL5 in transcription regulation, thereby contributing to gene 
regulation and cell cycle progression. Maintaining a proper intracellular balance of 
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MLL5 will also be important in providing a framework for proper cellular 
development as marginal alterations could serve as a determinant for the onset of 
diseases. Most importantly, elucidating the transcriptional and splicing regulation not 
only enable us to advance the knowledge of multilevel gene regulation in cells under 
physiological conditions but also provide opportunities to improve potential clinical 






















CHAPTER 2 – MATERIALS AND METHODS 
 
2.1 Cell lines and culture conditions 
 
Human cervical carcinoma HeLa, embryonic kidney cells HEK 293T, osteosarcoma 
U2OS, human colorectal carcinoma HCT116, human diploid fibroblasts WI38 and 
African green monkey kidney fibroblast-like cell line COS7 were cultured as 
monolayer in Dulbecco’s Modified Eagles Medium (DMEM, Gibco) in 25 cm2 tissue 
culture flasks. The cells were routinely passaged at 1:6 ratios (v/v) thrice weekly with 
the use of 1.0 ml of 0.25 % Trypsin-Ethylene-Diamine Tetracetic acid (EDTA) 
(GIBCO
®
). All cell lines were purchased from American Type Culture Collection 
(ATCC) (Manassas, VA, USA). For WI-38 cell line, cells with less than 10 passages 
were used for the experiments. The media was supplemented with 10% fetal bovine 
serum (FBS, Hyclone), L-glutamine (2mM) (Gibco), penicillin (100 units/ml) and 
streptomycin (100 µg/ml) at 37°C with 5 % CO2. This medium will be referred as 
complete medium in subsequent experiment. Transcriptional inhibitors were added to 
the complete media at the indicated final concentrations and duration: α-amanitin (10 
µg/ml, 8 h) (CalBioChem #129741); 5,6-dichlorobenzimidazole riboside (DRB, 100 
µM, 3 h) (CalBioChem #D1916); Actinomycin D (20 µg/ml, 2 h) (Sigma #A9415); 












 RNAi designer software (Invitrogen, Carlsbad, CA, USA) were used to 
identify potential siRNA targeting sites within human MLL5 mRNA sequence. Three 
different MLL5 specific siRNA duplexes (#1, #2 and #3) targeting nucleotide 
positions at 1063, 5215 and 6807 respectively, from the transcription starting point 
[National Centre for Biotechnology Information (NCBI) reference sequence: 
NM_182931.2]. Two different SC35 specific siRNA duplexes (#1 and #2) were 
designed to specifically target human SC35 mRNA sequence at nucleotide positions 
346 and 427 respectively from the transcription starting point [National Centre for 
Biotechnology Information (NCBI) reference sequence: NM_003016.4]. SC35 siRNA 
#2 was from Invitrogen (Stealth Select RNAi, SFRS2, Invitrogen). Scrambled siRNA 
was used as a control. All the siRNA duplexes were synthesized by 1st BASE 
(Singapore) and the sequences are summarized in Table 1. 
 
Cells were seeded one day before to achieve cell confluency of 40-60 % on the day of 
transfection. In performing siRNA transfection, cells were cultured in complete media. 
Transfection mixtures consist of Lipofectamine™ RNAiMAX (Invitrogen™) and 
siRNA were diluted with serum-free DMEM. The specific quantities of the reagent 
and siRNA added in preparation of the transfection mixes for the different cell culture 
vessels are summarised in Table 2. The transfection mix was incubated at room 
temperature (RT) for approximately 20 min to allow for the formation of siRNA 
duplex-Lipofectamine™ RNAiMAX complexes, before adding drop-wise into the 
cell culture vessels. To enhance the knockdown efficiency using MLL5 siRNA #2 and 
#3, as well as to achieve a knockdown efficiency that was comparable to MLL5 
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siRNA #1, a second transfection was carried out 24 h after the first. The cell media 
was subsequently changed 24 h post-transfection. Cells were cultured for 72 h post-
transfection, following which the cells were harvested for the necessary assays and 
experiments. Transfection efficiencies were analysed by Western Blot. 
 
Table 1: Nucleotide sequences of the siRNA used for MLL5 or SC35 gene 
silencing 
 
siRNA ID  siRNA sequences 
NC (Scrambled) Sense 5’-UUCUCCGAACGUGUCACGUdTdT-3’  
Antisense 5’-ACGUCACACGUUCGGAGAAdTdT-3’  
MLL5 #1 (1063) Sense 5’-CGCCGGAAAAGGGAAAAUAdTdT-3’  
Antisense 5’-UAUUUUCCCUUUUCCGGCGdTdT-3’  
MLL5 #2 (5215) Sense 5’- CAGCCCUCUGCAAACUUUCAGAAUUdTdT-3’ 
Antisense 5’-AAUUCUGAAAGUUUGCAGAGGGCUGdTdT-
3’ 
 MLL5 #3 (6807) Sense 5’-GCACUG GUUGGGCAUUUUAdTdT-3’ 
Antisense 5’-UAAAAUGCCCAACCAGUGCdTdT-3’ 
 SC35 #1 (346) Sense 5’-GCGUCUUCGAGAAGUACGGdTdT-3’ 
Antisense 5’-CCGUACUUCUCGAAGACGCdTdT-3’ 














Table 2: Optimised volumes as well as concentrations of Lipofectamine™ 
RNAiMAX (Invitrogen) and siRNAs used in preparation of the transfection 




































1 12 in100 1.6 in 100 1.0 12 
6-well 
plate 
2.5 24 in 200 3.2 in 200 2.0 12 
60mm 
plate 





Full length MLL5 and MLL5 deletion mutants used in this study were generated by 
flanking each PCR fragment of MLL5 cDNA with the FLAG sequence and cloning 
the fragments into the pEF6/V5-His-vector (Invitrogen) in frame with BamHI and 
XbaI sites (Liu et al., 2010).  
 
SC35 cDNA was amplified by PCR from total RNA prepared from HeLa cells using 
the forward primer 5’-
CGCGGATCCATGAGCTACGGCCGCCCCCCTCCCGATGT-3’ (with BamHI 
cutting site) and reverse primer 5’-CCGCTCGAGTTAAGAGGACACCGCTCCTT-
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3’ (with XhoI cutting site) and cloned in-frame into the pXJ40-HA vector with the 
conditions listed in Table 3. The PCR reaction was analysed by gel electrophoresis 
and the PCR product (666 bp) was purified directly from the PCR reaction mix using 
the PCR Purification Kit (Qiagen). DNA was eluted in 50µl of elution buffer (10mM 
Tris-Cl, pH 8.5). All the restriction enzymes (RE) used were purchased from New 
England Biolabs and the digestion reaction is summarised in Table 4. Ligation of the 
SC35 amplicon into the pXJ-HA vector was performed using T4 DNA ligation 
mixture (New England Biolabs). A total of 15µl ligation reaction was set up as shown 
in Table 5 and a negative control that consisted only the pXJ-HA vector was included. 
A 3:1 (vector: insert) ratio was used in the ligation process and the ligation mixture 
was incubated at 16°C overnight. The final construct, pXJ-HA-SC35, was verified by 
DNA sequencing. Subsequent sequences obtained were aligned against the relevant 
GenBank sequence using the Basic Alignment Search Tool (BLAST) from NCBI and 
in-frame fusions were also checked. 
 
Table 3: PCR reaction composition and conditions of pXJ-HA-SC35 
 
PCR reaction mix PCR conditions 
Reagent Quantity (µl) 1) Initial denaturation: 94°C for 3 min 
 
2) 35 cycles of 
a) DNA Denaturation: 94°C for 30 sec 
b) Primer annealing: 56.9 °C for 1 min  
c) DNA Extension: 68°C for 45 sec 
 
3) Final extension: 72°C for 10mins 
 
4) After cycling, the reaction is 
maintained at 18°C.  
10X High Fidelity PCR 
buffer 
5.0 
2 mM dNTP 1.0 
50 mM MgSO4 2.0 









Platinum® Taq High 
Fidelity 
0.2 






Table 4: Digestion reaction composition of pXJ-HA-SC35 
 
Table 5: Reaction composition for ligation of SC35 into pXJ-HA vector 
 
Reagent Ligation reaction (µl) Negative control (µl) 
10X T4 DNA ligase buffer 1.5 1.5 
T4 DNA ligase 0.5 0.5 
pXJ-HA vector (16ng/µl) 2.0 2.0 
SC35 insert (44ng/µl) 0.5 - 
Water 10 10.5 
Total 15  15 
 
 
2.4 Calcium-phosphate mediated DNA plasmid transfection 
 
293T cells were seeded on 60 mm plate to achieve approximately 50% cell 
confluency on the day of transfection. Calcium-phosphate method was used for 
introducing DNA into the cells. The transfection mixture for a typical 60mm dish is 
listed in Table 6. To a 1.5ml eppendof tube, DNA was added to the middle part of the 
water while CaCl2 was added to the bottom part of the water. This DNA-CaCl2 
mixture was mixed gently and thoroughly before transferred drop-wise to another 
1.5ml eppendof tube containing 2X HBS solution. This DNA-CaCl2–HBS mixture 
was mixed gently with the pipette till the solution is homogenous and this transfection 
mixture was incubated at room temperature for 30 min before adding drop-wise 
Component Insert (SC35) Vector (pXJ40-HA) 
Insert /Vector 30 µl 30 (100ng/µl) 
BamHI 1µl 1µl 
XhoI 1µl 1µl 
10X NEB buffer 3 5µl 5µl 
Bovine Serum Albumin (BSA) (10X) 5µl 5µl 
Water 8µl 6.5µl 
Calf Intestinal alkaline phosphatase 
(CIP) 
- 1.5µl 
Total 50µl 50µl 
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slowly into the cell culture vessel. After 24 h, fresh medium was given to the cells. 
Transfection efficiency was analyzed by Western Blot.  
 
Table 6: Transfection mixture using calcium-phosphate method for a typical 
60mm dish 
 
Components Volume (µl) 
DNA (100ng/ µl) Variable (3 to 6µg DNA)  
2.5M Calcium chloride solution 22 
Water Variable 
Add the DNA-calcium chloride mixture drop-wise into 2X HBS solution 





2.5 Cell lysate preparation, Immunoprecipitation and Western blot 
 
Total cellular protein extraction was performed by direct cell lysis using Laemmli 
sample buffer (62.5 mM Tris-HCl pH 6.8, 2.5% SDS, 10% glycerol, 0.01% 
bromophenol blue), boiled at 100°C for 3 min and sonicated for 20 sec at 30% output 
power when necessary (Sonics VCX130, Newtown, CT, USA). Cell lysates were 
made to a concentration of 20 million cells/ml. The buffers and conditions used for 
Western Blot can be found in Table 7 and Table 8 respectively. MLL5 protein is 
detected using either self-generated or commercially available atni-MLL5 antibodies 
listed in Table 9 while other proteins of interest are detected using commercial 




For immunoprecipitation studies, cells were lysed in lysis buffer supplemented with 
protease and phosphatase inhibitors (150 mM NaCl, 20 mM  Tris-HCl (pH 8.0), 1% 
Triton X-100, 2 mM phenylmethylsulfonyl fluoride, 2 µg/ml leupeptin, 2 µg/ml 
aprotinin, 1 µg/ml pepstatin A, 1 mM Na3VO4, and 5 mM NaF). In order to avoid 
protein degradation resulting from the inactivation of protease and phosphatase 
inhibitors, all subsequent steps involving the handling of the cell lysate were 
performed at low temperature on ice, where possible. The lysate were repeatedly 
passaged through a syringe needle (1 ml syringe with a 21 gauge size needle) to shear 
DNA and thus release the nuclear proteins. The lysates were then incubated on ice for 
30 mins before centrifugation at 13000rpm for 15 mins at 4
o
C. The pellet was 
discarded and supernatant retained. 10 μl of the cell lysate was used to test for 
transfection efficiency before the remaining cell lysate was subjected to 
immunoprecipitation. A pre-clearing step to remove non-specific binding was 
performed by incubating the cell lysate with 20 μl TrueBlot™ Anti-mouse / rabbit 
Immunoglobulin Immunoprecipitation (IP) beads (50% slurry) at 4
o
C for 1 h with 
continuous rotation. Pre-cleared lysate were then divided into two portions before 
incubation with antibodies or IgG (Table 9 and Table 10) respectively at 4
o
C for 2.5 h 
with continuous rotation. All steps were done on ice. IP Beads was washed twice with 
ice-cold 1X PBS before incubation with each of the cell lysate-antibody mixtures and 
rotated at 4
o
C for another 1.5 h. Following that, IP beads were spun down at 1000g 
for 5 mins. The supernatant were kept as flow-through at -80
o
C, in the event that pull-
down was not successful. The beads were washed once with ice-cold mild lysis buffer 
and twice with ice-cold 1X PBS. Proteins bound to the beads were then eluted with 60 
μl of Sodium Dodecyl Sulphate (SDS)/Dithiothreitol (DTT) (4:1 ratio) and boiled at 
100
o
C for 3 mins. The beads were then spun down at 13500 rpm for 2 mins to 
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dissociate the bound proteins. The supernatant was kept and analysis of Co-IP was 
performed by Western Blot.  
 





(protein < 150 
KDa) 
Transfer Buffer 
(protein ≥ 150 
KDa) 
TBS 
100 mM Tris base 
0.384 M glycine 
0.1% SDS 
25 mM Tris base 
150 mM glycine 
20% (v/v) methanol 
25 mM Tris base 






150 mM NaCl, 
2.5 mM KCl 
(adjust to pH7.5) 
 
Table 8: Conditions for Western Blot 
 










5% skim milk 
(Fluka
*
) in TBS 
5% skim milk 
(Fluka
*
) in TBS 
5% skim milk 
(Fluka
*























5% skim milk 
(Fluka
*
) in TBS 
5% skim milk 
(Fluka
*
) in TBS 
5% skim milk 
(Fluka
*






























5% BSA in 
TBS/0.05% 
Tween-20 
5% BSA in 
TBS/0.05% 
Tween-20 









Fluka skim milk, #70166; 
†
Anlene Gold Hi-Calcium Skimmed milk. 
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Table 9: Self-generated or commercial MLL5 antibodies used in Western blot, immunofluorescence and immunoprecipitation. 






IF IP WB 
MLL5-8009
*
 Alpha Diagnostic 1157-1170 - 1:100 15µg 1:5000 
MLL5-227* 
 
Alpha Diagnostic 227-241 - 1:100 - - 
MLL5 Abcam 75339 Abcam Synthetic peptide derived from the N terminal 75339 1:100 - - 
MLL5 Abgent 6186a Abgent Not disclosed on the product sheet 6186a 1:50 - - 
MLL5 Orbigen 10849 Orbigen Not disclosed on the product sheet 10849 1:50 - - 
MLL5 Santa Cruz L14 Santa Cruz Epitope mapping near the N-terminus of human 
MLL5 
 
68635 1:50 - - 
MLL5 Santa Cruz N20 Santa Cruz Epitope mapping near the N-terminus of human 
MLL5 
 
68635 1:50 - - 
*
 Polyclonal antibody against human MLL5 central region was raised in rabbits and purified using a Protein A column (GE Healthcare, Piscataway, NJ, USA) 
(Liu et al., 2010).   





Table 10: Commercial antibodies and beads used in Western blot, immunofluorescence and immunoprecipitation. 
Antibodies or Beads Manufacturer Catalogue  No. Dilution Factor 
IF IP WB 
PML SantaCruz sc-966 1:50 - - 
CBP SantaCruz sc-7300 1:50 - - 
CREST ImmunoVision HCT 0100 1:250 - - 
SC35  Sigma-Aldrich S4045 1:2000 - - 
SC35  BD Bioscience 556363 - - 1:200 
Sm BD Bioscience MS-450-P1 1:500 - - 
CDK9 SantaCruz sc-13130 - - 1:200 
CTD4H8 Millipore 05-623 1:1000 - 1:3000 
H5 Covance MMS-129R 1:50 - 1:250 
H14 Covance MMS-134R 1:50 - 1:250 
8WG16 Covance MMS-126R 1:50 - 1:250 
Cyclin T1 SantaCruz sc-8127 - 5µg 1:200 
H3K4-3Me Abcam Ab1012 1:100 - 1:2000 
H3K4-2Me Abcam Ab32356 - - 1:1000 
H3K4-1Me Abcam Ab8895-25 - - 1:1000 
H3K9-3Me Abcam Ab8898 1:250 - 1:1000 
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Histone H3 Cell Signalling 9715 - - 1:1000 
Acetyl Histone H4 Upstate 06-866 1:250 - 1:2000 
Brm Santa Cruz  - - 1:200 
Brg1 Santa Cruz  - - 1:500 
Baf155 Santa Cruz  - - 1:200 
FLAG M2 Sigma-Aldrich F3165 1:1000 - 1:2000 
HA SantaCruz sc-805 - - 1:500 
Tubulin SantaCruz sc-8035 - - 1:500 
Goat anti-mouse HRP-conjugated GE Healthcare RPN-4201 - - 1:10000 
Donkey anti-rabbit HRP conjugated Pierce (Thermo) 31238 - - 1:5000 




115-036-006 - - 1:5000 
anti-GFP, IgG, Alexa Fluor 488 conjugate Invitrogen 21311 1:250 - 1:2000 
anti-BrdU Alexa Fluor 594-conjugated Invitrogen A21304 1:250 - - 
Goat anti-mouse Alexa Fluor 568 -conjugated Invitrogen A11031 1:250 - - 
Chicken anti-rabbit Alexa Fluor 488 -
conjugated 
Invitrogen A11008 1:250 - - 
Goat anti-human Alexa Fluor 594-conjugated  Invitrogen A11014 1:250 - - 
Mouse IgG  SantaCruz sc-2025 5µg - - 
Mouse IgG Mouse beads (50% slurry) eBioscience #00-8811 - 20µl  
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2.6 Immunofluorescence microscopy 
 
Cells were grown on poly-D-lysine (1mg/ml) (Sigma, Cat No. 6403) coated 
coverslips and fixed with methanol at -20°C for 10 min, rehydrated with 1X PBS and 
blocked in 5% bovine serum albumin. Respective primary antibodies were diluted in 
blocking buffer and incubated overnight at 4°C. Samples were washed with PBS/0.05% 
Tween 20 thrice and incubated with secondary antibodies conjugated with Alexa 
Fluor 488 (green) or 568/594 (red) (Invitrogen) for 1 h. Antibodies used can be found 
in Table 9 and Table 10. DNA was stained with 4’ 6-diamidino-2-phenylindole, 
dihydrochloride (DAPI) (Invitrogen #D1306) and the coverslips were mounted with 
FluorSave reagent (Merck #345789) to preserve fluorescence. When necessary, at 
least 100 cells were counted for each sample. Images were acquired Olympus IX81 
microscope equipped with a cooled charge-coupled device camera (QImaging) and 
analyzed using QEDInVitro™ Version 3.2.2 and Image-Pro Plus 6.2 software 
(MediaCybernetics). 
 
2.7 Nuclease digestion 
 
Cells were fixed in methanol for 10 min at -20°C, rinsed in 1X PBS and incubated in 
RNase A (100 µg/ml in PBS, DNase free) (Sigma) for 2 h at 25°C. After several 
washes with 1X PBS, cells were prepared for immunofluorescence microscopy as 
described above.  Heat-shock experiment was done in petri dishes containing 
coverslips and pre-warmed medium was incubated in a 45°C oven for 15 min prior to 
fixation for immunofluorescence microscopy. Control cells were also transferred to 
dishes and incubated for the same duration in medium kept at 37°C.  
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2.8 RNA extraction, cDNA synthesis and semi-quantitative real-time PCR 
(qPCR) 
 
Total RNA was extracted using TRIzol reagent (Invitrogen #15596-026) and the 
cDNA was synthesized using iScript
TM
 cDNA synthesis kit (Bio-Rad, Hercules, CA, 
USA). About 1 million cells were collected by trypsinization, followed by 
centrifugation at 200 x g for 3 min at 4°C. Cell pellet was homogenized in 1 ml 
TRIzol reagent for 5 min at room temperature. Chloroform (200 µl) was added to the 
homogenized sample and mixed vigorously for 15 sec. After incubation for 5 min at 
room temperature and centrifugation at 13 000rpm for 15 min at 4°C, the upper 
aqueous phase (450 µl) was transferred to a new RNase-free eppendorf tube. RNA 
was precipitated by addition of 0.5 ml isopropanol and collected by centrifugation at 
13 000rpm for 10 min at 4°C. The RNA pellet was washed with 75% ethanol 
(prepared using absolute ethanol and nuclease-free water), briefly air-dried, and 
dissolved in nuclease-free H2O (Ambion, #AM9939). The RNA concentration was 
determined by measurement of absorbance at 260 nm using NanoDrop 2000c 
(Wilmington, DE, USA).  
 
For cDNA synthesis, RNA that was extracted from cells was converted to cDNA 
using the cDNA synthesis kit with random hexamer primers (Biorad) and iCycler 
(Bio-Rad) machine. The reaction mix (20 µl) and the conditions were set up as shown 






Table 11: cDNA synthesis conditions  
 
cDNA reaction mix cDNA conditions 
Reagent Quantity (µl) 1) 5 min at 25°C,  
 
2) 30 min at 42°C 
 
3) 5 min at 85°C 




Random hexamers 1.0 
RNA (up to 1.5 µg) Variable 
Nuclease free water Variable 
Total 20.0 
 
For semi-quantitative real time PCR (qPCR), KAPA SYBR FAST One-step qPCR 
Master mix is used. The various gene expression levels were measured using the iQ5 
qPCR machine (Biorad) and in-house designed primers (Table 12). The reaction mix 
(50 µl for triplicates of each gene to be studied) and qPCR conditions are summarized 
in Table 13.   
 
Table 12: Primers used in qPCR  
 
Primers  Sequence 
MLL5 Sense 5’ - CCA CCA CAA AAG AAA AAG GTT  TCT C -3’ 
Antisense 5’- GTG TTG GTA AAG GTA GGC TAG C – 3’   
GAPDH  Sense 5’-GTG AAG GTC GGA GTC AAC G-3’ 
Antisense 5’ TGA GGT CAA TGA AGG GGT C -3’   
S14 Sense 5’- GTT TTG CTT CAG GGA GGA GCT T-3’ 










Table 13: qPCR reaction mixture and conditions 
 
qPCR reaction mix qPCR conditions 
Reagent Quantity (µl) 1) Inactivate reverse transcriptase: 
95°C for 5 min 
 
2) PCR cycling and detection - 40 
cycles  
a) Denaturation: 95°C for 3 sec 
b) Annealing / Extension: 60°C for 
20 sec (data acquisition step) 
 
3) Melt curve analysis 
95°C for 1 min 
55°C for 1 min 
55°C for 10 sec (80 cycles, 




 FAST qPCR 
Master Mix (2X) 
25 
Forward Primer (10 μM) 1.0 
Reverse Primer (10 μM) 1.0 
RNA (100ng) Variable 
KAPA RT Mix (50X) 1.0 
Nuclease free water Variable 
Total 50.0 
 
2.9 Splicing assay 
 
Splicing efficiency assays were performed as described by (Nasim et al., 2002). 
Briefly, cells were seeded in a 6 well-plate and MLL5 knockdown was done the next 
day after cell plating. 24 h after knockdown, pTN23 plasmid was transfected into 
293T using calcium phosphate method as described in Section 2.4. To ensure that 
MLL5 level remained minimal in the cell, knockdown was done again 24 h after 
transfection. In all, MLL5 knockdown was done for 72 h and over-expression of 
pTN23 was done for 48 h. After which, cells were harvested from each well of the 6-
well plate and the final cell pellet was re-suspended in 1 ml 1X PBS. 3/5 of the cell 
suspension was used for RNA extraction, 1/5 was kept for Western blot to check for 
MLL5 knockdown efficiency and the remaining 1/5 of the cell suspension was used 




To measure luciferase activities, cell pellet was lyzed in 150 µl of 1X passive lysis 
buffer for 30 min at room temperature with gentle rocking on an orbital shaker. After 
that, the lysates were transferred to a tube and centrifuged at 1000 rpm for 5 min. The 
supernatant (around 120 µl) was equally distributed for luciferase and β-galactosidase 
activities. Triplicates of each assay were done in a 96-well flat bottom micro-titer dish 
and 20 µl of the supernatant was used each time. 100 µl of Luciferase Assay Reagent 
(LAR II) was dispensed into each well and mixed by pipetting 3 times before placing 
the dish in the luminometer (Tecan) to measure the luciferase reading. The 
luminometer was programmed to perform a 2-second pre-measurement delay, 
followed by a 10-second measurement period for each reporter assay. Normalization 
of luciferase reading by β-galactosidase reading was carried out before comparisons 
were made. 
 
To measure β-galactosidase activity, 20 µl of cell lysate was added into a 96-well flat 
bottom micro-titer dish. For each well, 140 µl of Buffer A- β-mercaptoethanol was 
added and this buffer was prepared in the following way: 160 µl Buffer A-β-
mercaptoethanol mixture constituted 8 µl of 1M β-mercaptoethanol and 152 µl Buffer 
A. Mix the two components by inversion. The final volume in each well was 160 µl. 
The micro-titer dish was covered and incubated for 5 min at 37°C. After which, 50 μl 
of o-Nitrophenyl-β-D-galactopyranoside (ONPG) substrate was added to each well 
and the micro-titer dish was covered with a micro-titer dish lid. The dish was then 
incubated in an incubator at 37°C until the mixture turned bright yellow. To terminate 
the reaction, 90 μl of stop solution was added and the micro-titer dish was scanned in 
a micro-titer dish reader that was set at 415nm. The incubation period was recorded 
and this was the time expired between the addition of ONPG substrate and the 
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addition of the stop solution. The optimal OD415 reading is between 0.6 to 0.9. Table 
14 summarized the preparation of media and reagents required for β-galactosidase 
activity.  
 




Buffer A–β-Mercaptoethanol Mixture (pH 
7.5) 
Prepare fresh before each assay. 
Buffer A 
100 mM NaH2PO4 
10 mM KCl 
1 mM MgSO4 
 
50 mM β-Mercaptoethanol 
o-Nitrophenyl-β-D-Galactopyranoside 
(ONPG) 
4 mg/ml in 100 mM NaH2PO4 buffer 
(pH 7.5) 
Stop solution 1 M Na2CO3 
 
 
To determine the splicing efficiency through reverse transcription polymerase chain 
reaction (RT-PCR), cell lysates were harvested and RNA extraction and cDNA 
synthesis was performed as described in Section 2.8. A 50 µl reaction mix was set up 
as shown in Table 15 and the primers used are as follows: GalF 3301.forward (5’-
AACATCAGCCGCTACAGTCAA-3’) and LucR 3700 (5’-ACGTGATGT 







Table 15: RT-PCR conditions  
 
PCR reaction mix PCR conditions 
Reagent Quantity (µl) 1) Initial denaturation: 94°C for 3 min 
 
2) 35 cycles of 
a) DNA Denaturation: 94°C for 30 sec 
b) Primer annealing: 56.9 °C for 1 min  
c) DNA Extension: 68°C for 45 sec 
 
3) Final extension: 72°C for 10mins 
 
4) After cycling, the reaction is 
maintained at 18°C.  
10X High Fidelity PCR 
buffer 
5.0 
10 mM dNTP 1.0 
25 mM MgSO4 4.0 






Template  2.0  
Applied Biosystem (ABI) 
Taq 
0.5 




2.10 Bromo-uridine Triphosphate (Br-UTP) incorporation in permeabilized cells 
 
To label nascent RNA, intact cells were incubated in 7.5mM Br-uridine (Sigma 
#850187) for 3 h. Cells were rinsed with 1X PBS before being fixed in 4% 
paraformaldehyde for 10 min at room temperature and permeabilized in PBS/0.5% 
Triton X-100 for 5 min prior to immuno-staining. Incorporated Br-UTP was detected 
with anti-BrU antibody at 4°C overnight and incubated for at least 1 h with Alexa 
596-conjugated goat anti mouse IgG at room temperature. 
 
2.11 Micrococcal nuclease (MNase) accessibility assay 
 
MNase assays were performed as described by (Knoepfler et al., 2006). Briefly, 
U2OS cells were seeded in a 6 well-plate and subjected to scrambled or MLL5 
siRNAs (#1 or #2+#3) for 72 h before harvest. The procedure for the MNase assay 
constituted five main steps: i) cell permeabilization, ii) MNase digestion of 
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permeabilized cells, iii) organic extractions of MNase digested DNA, iv) DNA 
precipitation and v) quantitation and assessment of DNA. The components of the 
buffers used are listed in Table 16.  
 
i) Cell Permeablization 
 
Unless otherwise stated, reaction was done at room temperature. To each well of a 6-
well plate, the medium from the cells was aspirated and 850µl room temperature (RT) 
permeabilization solution 1 (PS1) was added. After which, PS1 was removed and 
cells were treated with 0.025% lysolecithin (diluted from 1 mg/ml stock in 37◦C 
permeabilization solution 1 to 480µl total volume) at room temperature for 2 min. The 
solution was removed from the plate and 850µl of room temperature PS1 (without 
lysolecithin) was added. 
 
ii) MNase digestion of permeabilized cells 
 
After aspirating the ssolution from plate, 480µl of RT permeabilization solution 2 
(PS2) containing 0, 6.25, 12.5, 25, 50 and 100 Units MNase respectively was added 
into each well and the solution was incubated for 5 min at RT. After which, the 
solution was discarded and 480µl 2× TNESK solution was added with gentle swirling 
to ensure complete cell lysis. Then, 480µl lysis dilution buffer was added and the 
resultant mixture was transferred to a 15-ml conical polypropylene tube. The tube was 







iii) Organic extractions of MNase digested DNA 
 
The cell lysate was diluted with 1 volume TE buffer, pH7.9 and 1 volume of 
neutralized phenol was added. The tube was inverted sharply several times before 
placing on a gentle shaker for 15 min. The samples were then centrifuged for 5 min at 
2000 rpm. The upper aqueous layer was then transferred to a fresh tube. 1 volume of 
chloroform was added and the tube was inverted sharply several times before gently 
shaking for 15 min. The upper aqueous phase was obtained after centrifuging for 5 
min at 2000 rpm. 1/10 volume of 3 M sodium acetate was then added and the mixture 
was mixed by inversion.  
 
iv) DNA precipitation  
 
2.5 volumes of 95% ethanol was added to the above mixture and inverted gently for 
20 times before incubating at −20◦C overnight. The next day, the mixture was 
centrifuged for 10 min at 10 000 X g and the supernatant was discarded. 0.5 ml of 70% 
ethanol was then added and gently inverted before centrifuging for another 2 min. 
After that, the supernatant was discarded and the pellet was dried for 5 min before the 
DNA was re-suspended in 100 µl TE buffer. 
 
v) Quantitation and assessment of DNA 
 
Finally, the concentration of the DNA was measured and 0.5 μg of each DNA sample 
was loaded onto a 1.2% agarose gel to assess the level of endogenous nuclease and 
MNase cleavage of the chromatin.  
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150 mM sucrose 
80 mM KCl 
35 mM HEPES, pH 7.4 
5 mMK2HPO4 
5 mMMgCl2 
0.5 mM CaCl2 
Permeabilization solution 
2 (PS2) 
150 mM sucrose 
50 mM Tris·Cl, pH 7.5  
50 mM NaCl 
2 mM CaCl2 
2X TNESK  20 mM Tris·Cl, pH 7.4  
0.2 M NaCl 
2 mM EDTA 
2% SDS 
0.2 mg/ml proteinase K (add just before use) 
Lysis dilution  150 mM NaCl 













CHAPTER 3 – RESULTS 
 
3.1 Co-localization of MLL5 with the spliceosome components  
 
Our group has previously demonstrated that MLL5 forms intra-nuclear foci in 
interphase cells (Deng et al., 2004); however, its biological functions remain unclear. 
To investigate the possible biological processes involved, we first examined the co-
staining pattern of MLL5 with several well-characterized proteins that are known to 
display nuclear speckle pattern by immunofluorescence staining in HeLa cells. These 
proteins include CREB binding protein (CBP), kinetochore associated protein using 
CREST antibody, promyelocytic leukaemia (PML), spliceosome proteins like splicing 
factor SC35 and smith antigens (Sm). α-Sm antibody is directed against 7 proteins 
(B/B', D1, D2, D3, E, F, G) that constitute the common core of U1, U2, U4 and U5 
small nuclear ribonucleoprotein particles (snRNP antigens) of the spliceosome 
complex. Surprisingly, MLL5 showed a high degree of co-localization with the 
spliceosome protein SC35 but not with the other proteins tested (Figure 5). Such co-






Figure 5: Co-localization of MLL5 with the spliceosome components. HeLa cells 
were co-stained with anti-MLL5-8009 antibody and other known proteins that 
displayed nuclear speckle pattern. These proteins include CREB binding protein 
(CBP), kinetochore associated protein using CREST antibody, promyelocytic 
leukaemia (PML), spliceosome proteins like smith antigens (Sm) or splicing factor 
SC35. MLL5 showed a close resemblance to nuclear speckles associated with the 
spliceosome complex, SC35 and Sm. Arrows indicated coiled bodies observed in the 
nucleoplasm when stained with anti-Sm antibody. These coiled bodies were not 








The above co-localization was observed using anti-MLL5 antibody (designated as α-
MLL5-8009) that recognised the central region of MLL5 (amino acids 1157–1170). 
We have also attempted to test the co-localization between MLL5 and SC35 with 
other self-generated anti-MLL5 antibodies that recognised other epitopes on MLL5 as 
well as commercially available anti-MLL5 antibodies. Anti-MLL5-227 antibody 
recognised amino acid residues 227-241 of full length MLL5. As shown in Figure 6, 
anti-MLL5-8009 antibody showed the most distinct MLL5 speckles and the extent of 
overlap between MLL5 and SC35 was the greatest. Therefore throughout this study, 
anti-MLL5-8009 antibody would be used to probe for full length MLL5 on Western 
Blot, immunoprecipitation and immunofluorescence. Faint or no signals (even at a 
low dilution factor of 1:25) were obtained with the other commercially available 
antibodies, except for a polyclonal anti-MLL5 antibody (Abcam #75339). These 
drastic differences in immunofluorescence signals could be attributed to the quality 
and specificities of various anti-MLL5 antibodies, where the specificities of the 
antibodies are largely dependent on the epitope to which the antibodies have been 
designed to recognise. In addition, these commercial antibodies also gave faint or no 
signals on Western Blot. To our knowledge, the crystal structure of MLL5 is still 
unknown; hence, it remains a challenge towards designing a good MLL5 antibody for 








Figure 6: Different anti-MLL5 antibodies and their co-localization with SC35.  
Comparing the different anti-MLL5 antibodies currently available, anti-MLL5-8009 
antibody which recognised amino acid residues 1157 to 1170 of full length MLL5 
showed the most distinct MLL5 speckles staining and the extent of overlap with SC35 
was the greatest. Anti-MLL5-227 antibody recognised amino acid residues 227 to 241. 
Among the commercial antibodies, only a polyclonal anti-MLL5 antibody (Abcam 
#75339), showed the most promising immunofluorescence staining capabilities. 
However, the specific recognition site of this antibody on the N terminal of MLL5 is 





To further verify the association with the spliceosome complex and to validate that 
the co-localization of MLL5 with the spliceosome components was not cell-type 
specific, we examined another spliceosome protein, smith antigens (Sm) along with 
SC35 in five human cell lines (293T, COS7, HeLa, U2OS, and WI38). Among these 
cell lines, 293T and COS7 are transformed cell lines; HeLa and U2OS are tumor cell 
lines while WI38 is a normal diploid fibroblast cell line. Anti-Sm antibody used was 
directed against seven proteins (B/B', D1, D2, D3, E, F, G) that constituted the 
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common core of U1, U2, U4 and U5 small nuclear ribonucleoprotein particles 
(snRNP antigens) of the spliceosome complex. Similar to SC35, the staining pattern 
of anti-MLL5-8009 antibody overlapped extensively with the snRNP antigens. The 
high degree of co-localization between MLL5 and spliceosome components was 













Figure 7: Co-localization of MLL5 with the spliceosome components in different 
cell lines. Co-localization between MLL5 and the spliceosome components were 
consistent across five human cell lines (293T, COS7, HeLa, U2OS, and WI38). 
Among these cell lines, 293T and COS7 are transformed cell lines; HeLa and U2OS 
are tumor cell lines while WI38 is a normal diploid fibroblast cell line. Bar: 5 µm. 
 
 
3.2 Localization of MLL5 and spliceosome components in response to nuclease 
and heat-shock treatment  
 
It has previously been demonstrated that SC35 and snRNP antigens co-localized 
within the interchromatin granule clusters (IGCs) and perichromatin fibrils (PFs) but 
their localizations within these nuclear structures displayed different nuclease 
sensitivities (Spector et al., 1991). This suggested that spliceosome components might 
localize through different molecular interactions. To determine the molecular basis 
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responsible for the association of MLL5 with the spliceosome components, the sub-
nuclear distribution of MLL5 in response to heat-shock and RNase A treatments were 
examined and compared to that of SC35 and snRNPs in HeLa cells by 
immunofluorescence staining.  
 
As shown in Figure 8, cells digested with RNase A showed no alteration in the 
speckle morphology for both MLL5 and SC35. MLL5 and SC35 still co-localize 
extensively in RNase-A treated cells. However, RNase A-treated cells labelled with 
anti-Sm antibody not only showed an overall decrease in the fluorescence intensity of 
the snRNP antigens, these speckles also became diffusely distributed. These 
observations for snRNP antigens were consistent with previous report (Spector et al., 
1991). These observations demonstrated that although MLL5 and the splicing 
components co-localized in the same nuclear speckle compartment, MLL5 evoked a 
response that preferentially resembled that of SC35 as compared to the snRNPs.  
 
Heat-shock treatment was previously performed in Drosophila (Yost and Lindquist, 
1986) and mammalian cells (Bond, 1988) to inhibit pre-mRNA processing where U2 
and U4/U5/U6 components were found to be disrupted in heat-shock treated cells 
(Bond, 1988; Shukla et al., 1990). Such treatment elicited a re-distribution and a 
decrease in the fluorescence intensity of the snRNP speckles except for the coiled 
bodies which remained visible in the nucleoplasm. Unlike snRNP speckles, SC35 
speckles aggregated into rounded clusters and became enlarged with less evident 
interconnections (Spector et al., 1991). To determine the effect of heat-shock on 
MLL5, HeLa cells were heat-shocked for 15 min at 45°C before examining the 
cellular localizations of MLL5, SC35 and snRNP. Control cells were incubated for the 
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same duration in pre-warmed medium kept at 37°C. As seen in Figure 8, while the 
speckled pattern of MLL5 appeared evenly distributed in control cells; after heat-
shock, MLL5 speckles became less apparent. We speculate that the decreased speckle 
signals were likely due to the heat sensitivity of MLL5. Such heat sensitivity made the 
comparison for the co-localization pattern of MLL5 with SC35 or Sm in response to 
heat-shock treatment difficult. Nonetheless, previous RNase A treatment results might 






Figure 8: Association of MLL5 with splicing factor SC35 under RNase A 
digestion and heatshock. HeLa cells were treated with RNase A (100µg/ml) for 2 h. 
No change in the distribution pattern of MLL5 or SC35 under RNase A treatment was 
observed and both proteins were still co-localizing extensively. However, such 
treatment altered the speckled distribution of snRNP antigens as the speckles become 
significantly reduced and diffused throughout the nucleoplasm but the coiled bodies 
remain evident in the nucleoplasm. HeLa cells exposed to heat shock at 45°C for 15 
min caused MLL5 speckles to become less evident as compared to the control cells. 
SC35 speckles not only become enlarged and rounded; the interconnections between 
the speckles also became less apparent. Instead of appearing as enlarged speckles, 
snRNP antigens appear to be uniformly distributed throughout the nucleoplasm 
excluding the nucleoli. Bar: 10µM.   
 
 
3.3 Association of MLL5 and SC35 
 
The high degree of co-localization between MLL5 and SC35 encouraged us to test if 
MLL5 physically interacted with SC35. Full-length MLL5 and its deletion fragments, 
MLL5-ΔCT (1-1150aa), MLL5-ΔPS (562-1858aa), MLL5-ΔCD (Δ562-1150aa) and 
MLL5-CD (562-1150aa) (Figure 9) tagged with FLAG epitope were co-transfected 
with hemagglutinin (HA)-tagged SC35 into 293T cells, followed by 
immunoprecipitation with anti-FLAG antibody. As shown in Figure 9, full-length 
MLL5 interacted with SC35 and the strongest affinity with SC35 was observed in the 
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deletion mutant that retained the central domain and the C-terminus (MLL5-ΔPS). 
Central domain alone (MLL5-CD) showed less affinity to SC35 as compared to 
MLL5-ΔPS, suggesting that the presence of C-terminal domain would enhance its 
association to SC35. Nonetheless, the key region responsible for the interaction was 
the central domain since the deletion mutant (MLL5-ΔCD), lacking the central 






Figure 9: Association of MLL5 with splicing factor SC35. (Top) A schematic 
representation of MLL5 and its deletion fragments, MLL5-ΔCT (1-1150aa), MLL5-
ΔPS (562-1858aa), MLL5-ΔCD (Δ562-1150aa) and MLL5-CD (562-1150aa) aa, 
amino acids. (Bottom) Full length MLL5 and various deletion mutants were 
immunoprecipitated (IP) from 293T cell lysates with anti-FLAG antibodies and 
detected by anti-HA or anti-FLAG antibodies. MLL5-CD is the key region 
responsible for the interaction with SC35. The numbers indicate the molecular masses 
(kDa) of the protein standards. WB, Western blot. CT, C terminus. CD, Central 







3.4 Alteration in MLL5 protein level induced the re-distribution of SC35 to 
enlarged speckle domains 
 
It has been reported that the disassembly of inter-chromatin granule clusters as a 
result of transcription or pre-mRNA inhibition induced SR proteins such as SC35 to 
accumulate in enlarged nuclear speckles (Bregman et al., 1995). Since the localization 
of splicing factors in the nucleus has been demonstrated to be highly dynamic, we 
wanted to know if the physical association of MLL5 with SC35 was important for the 
dynamic structure of the speckle morphology.  
 
We began by examining the expression level and cellular localization of SC35 upon 
down-regulation of MLL5. U2OS cells were transfected with two different MLL5 
siRNAs (MLL5-siRNA #1: targets to the coding sequence; MLL5-siRNA #2 and 
MLL5-siRNA #3: target to the 3’untranslated region) for 3 days before analysis by 
Western blotting or immunofluorescent staining. In this study, MLL5-siRNA #2 and 
MLL5-siRNA #3 are used in combination to obtain a knockdown efficiency that is 
comparable to MLL5-sRNA #1. As seen in Figure 10, no effects on SC35 protein 






Figure 10: SC35 protein expression remains unaltered in MLL5 depleted cells. 
Total cell extract was prepared after U2OS cells were transfected with negative 
control (NC) or MLL5-siRNA (#1 or #2+#3) for 72 h. The expression of MLL5, 
SC35 and α-tubulin were studied by Western blotting. The expression of SC35 was 
not affected in MLL5-depleted cells as compared to NC-treated cells. 
 
 
Interestingly, knockdown of MLL5 resulted in enlarged, dot-like-SC35 speckles that 
lacked interconnections in contrast to NC-treated cells that displayed irregularly 
shaped SC35 speckles that appeared to be interconnected via a reticular network 
(Figure 11 Top). Phenotypes observed were scored through random selection of cells 
(n > 100 cells per sample) and categorised into 3 groups (Figure 11 Bottom): Normal 
(cells that exhibit irregular, punctate speckles with interconnections), Enlarged (cells 
that exhibit large spherical speckles without interconnections) and Others (cells that 
exhibit no speckles or a mixture of traits present in Normal and Enlarged groups). In 
NC-siRNA treated cells, 95% (COS7) and 96% (U2OS) exhibited typical SC35 
speckle morphology (Normal group) while 5% (COS7) and 4% (U2OS) deviated 
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from this normal group (Enlarged + Others). In MLL5-siRNA #1 treated cells, there 
was an approximately 10-fold increase in the enlarged population:  55% (COS7) and 
40% (U2OS) displayed enlarged SC35 speckles as compared to NC-siRNA-treated 
cells. More than 50% of MLL5-siRNA #1 treated cells displayed the enlarged 














Figure 11: Alteration in MLL5 protein levels by RNA interference induced the 
re-distribution of SC35 to enlarged speckle domains. (Top) MLL5 depletion 
resulted in an enlargement of SC35 nuclear speckles with less evident 
interconnections as compared to the NC-siRNA treated cells in both cell lines, COS7 
and U2OS. (Bottom) Phenotypes observed were scored through random selection of 
cells (n > 100 cells per sample) and categorized into 3 groups: Normal (cells that 
exhibit irregular, punctate speckles with interconnections); Enlarged (cells that exhibit 
large spherical speckles without interconnections) and Others (cells that exhibit no 







We also examined if ectopic over-expression of MLL5 would affect the cellular 
localization of SC35. 293T cells were transiently transfected with GFP-MLL5. After 
48 h, cells were fixed and stained with anti-SC35 antibody. Similar to the results 
obtained from MLL5 knockdown, 90% of GFP-MLL5 positive cells displayed an 
enlargement of SC35 speckles; in contrast, only 1% of GFP-MLL5 negative cells 
exhibited enlarged SC35 speckles (Figure 12). Our findings suggest that changes in 
the protein homeostasis of MLL5 have an effect on the dynamic nuclear distribution 
of SC35. In addition, recent studies have suggested that SC35 is necessary to promote 
RNAPII elongation in a subset of genes and participate in the bi-directional coupling 
between transcription and splicing (Milne et al., 2005; Caslini et al., 2009). This raises 


















Figure 12: Exogenous introduction of MLL5 induced the re-distribution of SC35 
to enlarged speckle domains. Ectopic over-expression of GFP-MLL5 in 293T cells 
resulted in an enlargement of SC35 speckles in GFP positive cells. Phenotypes 
observed in GFP negative and GFP positive cell populations were tabulated. More 
than 90% of GFP-positive cells displayed an enlargement of SC35 speckles as 





3.5 Multiple transcription inhibitors induce MLL5 to redistribute to enlarged 
speckles 
 
Nuclear speckles are dynamic structures implicated in the spatial coordination of 
transcription and splicing (Misteli and Spector, 1999; Sacco-Bubulya and Spector, 
2002). Such enlarged, dot-like SC35 speckles have previously been suggested to be an 
indication of altered splicing and/or transcription activity (O'Keefe et al., 1994). To 
examine the effect of transcription inhibition on the distribution of MLL5 speckles, 
we first employed several transcriptional inhibitors that exhibited different 
mechanism of actions, including α-amanitin (Bushnell et al., 2002), 5,6-dichloro-1-ß-
D-ribobenzimidazole (DRB) (Tamm et al., 1976; Chodosh et al., 1989), Actinomycin 
D (Perry and Kelley, 1970) and Roscovitine (Ljungman and Paulsen, 2001). As 
shown in Figure 13, in transcriptionally active nuclei (absence of inhibitors), the 
distribution pattern of MLL5 largely resembled that of SC35 and both MLL5 and 
SC35 speckles co-localized extensively. In transcriptionally inactive nuclei (presence 
of inhibitors), speckle morphology of both MLL5 and SC35 changed dramatically, 
from the normal irregularly shape to large rounded speckles without interconnections. 
Under each drug treatment, such enlargement of nuclear speckles observed for SC35 
was consistent with previous studies showing a modification in the speckle 
morphology when cells were stimulated with transcription inhibitors (Lallena and 
Correas, 1997; Shopland et al., 2002). Altogether, the data suggest that MLL5 
associates with SC35 in a specific nuclear compartment and is sensitive to the 
transcriptional state. Down-regulation of MLL5 with MLL5-siRNA, exogenous 
overexpression of GFP-MLL5 or the addition of transcription inhibitors led to an 





Figure 13: Multiple transcription inhibitors induce MLL5 to redistribute to 
enlarge speckles. HeLa cells were treated with various transcription inhibitors at the 
respective final concentrations and duration: α-amanitin (10 µg/ml, 8 h), 5,6-
dichlorobenzimidazole riboside (DRB, 100 µM, 3 h), Actinomycin D (20 µg/ml, 2 h) 
(Sigma #A9415) and Roscovitine (25µM, 1.5 h). Control cells have irregularly shaped 
speckles with apparent interconnections while in transcription inhibited cells, speckles 









3.6 Intra-nuclear reorganization of MLL5 speckles is reversible and temperature 
dependent 
 
The transcriptional inactivator, DRB, is an adenosine analogue that suppresses 
RNAPII transcription by inhibiting the protein kinases that phosphorylate RNAPII 
CTD (Zandomeni and Weinmann, 1984; Stevens and Maupin, 1989). Cells incubated 
with DRB caused pre-mRNA splicing proteins to be re-distributed. Unlike α-amanitin 
that binds tightly and directly to RNAPII and inhibit transcription irreversibly, DRB 
can diffuse rapidly into the cell membrane and wash-out easily to reverse the 
transcriptional block (Tamm et al., 1976). Using DRB wash-out experiment, the 
redistribution of MLL5 and SC35 was found to be reversible and temperature 
dependent. After HeLa cells were treated with DRB for 3 h, both MLL5 and SC35 
speckles were transformed from the usual irregular shaped speckle pattern to 
unconnected rounded dots as seen in Figure 14. After DRB wash-out, the cells were 
maintained at 37°C or 4°C for 1 h. For cells that were incubated at 37°C after the 
wash-out, MLL5 and SC35 speckles reverted back to the original pattern and co-
localized extensively. Such phenotype was markedly different from those cells 
incubated at 4°C after the wash-out where MLL5 and SC35 speckles still remain 
enlarged without interconnections. This data complements our earlier observations 
that the speckle pattern of MLL5 correlates with the overall transcriptional activity of 
the cell. Both MLL5 and SC35 are likely to redistribute through a common 






Figure 14: Re-distribution of MLL5 speckles is temperature dependent. 
Intranuclear re-distribution of MLL5 speckles is reversible and temperature dependent. 
HeLa cells were initially treated with DRB at 100µM for 3 h. Thereafter, DRB 
medium was washout before fresh complete media was introduced. Each of the dishes 
was maintained at 37°C or 4°C for 1 h prior to fixation and labelled with anti-MLL5 
and anti-SC35 antibodies. MLL5 and SC35 speckles remained enlarged in DRB 
washout and maintained at 4°C as opposed to the dish at 37°C.  Bar: 10µM 
 
 
3.7 Alteration in MLL5 expression triggered transcription block 
 
Next, we would like to examine whether knockdown of MLL5 may have an impact 
on the transcriptional efficiency of RNAPII. We assessed the activity of RNAPII by 
measuring the transcript levels of ribosomal subunit S14 which has been previously 
reported by Leuenroth and colleagues (Leuenroth and Crews, 2008) as an approach to 
monitor RNAPII activity. Cells were grown for 72 h to ensure efficient knockdown by 
the respective MLL5 siRNAs. MLL5-siRNA #2 and MLL5-siRNA #3 were used in 
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combination to achieve a knockdown efficiency that was comparable to MLL5-
siRNA #1. Subsequently trizol extraction was performed to extract the RNA for 
further analysis by semi-quantitative real time PCR (qPCR). As shown in Figure 15, 
ribosomal protein S14 transcript that was transcribed by RNAPII showed a significant 




Figure 15: Gene expression of S14 ribosomal subunit after MLL5 knockdown. 
U2OS cells were treated with the respective MLL5 siRNAs for 72 h before the cells 
were harvested for semi-quantitative real time PCR (qPCR). MLL5 siRNA #2 and 
MLL5 siRNA #3 were used in combination to achieve a knockdown efficiency that 
was comparable to MLL5 siRNA #1. As compared to the NC- siRNA treated cells, 






As an alternative method to demonstrate how MLL5 participates in transcription, we 
performed 5-bromouridine 5 -´triphosphate (Br-UTP) incorporation experiment in 
MLL5-siRNA treated cells. Such Br-UTP incorporation experiment has been used by 
several groups to illustrate that RNAPII transcripts were predominantly distributed in 
several hundred foci throughout the nucleoplasm and to examine the sites of RNA 
synthesis in vivo (Jackson et al., 1993; Wansink et al., 1993). U2OS cells were treated 
with MLL5-siRNA(#1 or #2 + #3) or Actinomycin D, a known transcription inhibitor 
that suppressed transcription by intercalating with DNA and inhibiting RNA synthesis 
(Sobell, 1985). Prior to paraformaldehyde fixation, cells were treated with 7.5mM Br-
UTP for 3 h. In NC-siRNA treated cells, 96.5% were Br-UTP positive. Strikingly, in 
MLL5-depleted cells, more than 90% were Br-UTP negative (Figure 16). This 
observation was comparable to Actinomycin D-treated cells. Taken together, these 












Figure 16: Alteration in MLL5 expression by RNA interference triggers transcription block. (Left) Br-UTP incorporation was tabulated in 
the respective MLL5 siRNA-treated cells and Actinomycin D-treated cells. (Right) In the negative control (NC), cells are Br-UTP positive. Br-
UTP incorporation was abrogated in MLL5 knockdown cells. Actinomycin D, a known transcription inhibitor, was used as a positive control.  
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To study the effect of MLL5 up-regulation on transcription, ectopic over-expression 
of GFP-MLL5 was performed in 293T and Br-UTP incorporation was examined by 
immunofluorescence staining. The expression level of GFP-MLL5 was observed by 
the intensity of green fluorescence in cells that were successfully transfected (Figure 
17, Top) and categorised into 3 groups (Figure 17, Bottom): Strongly expressed 
(GFP
Bright
), Weakly expressed (GFP
Dim





group, more than 90% were Br-UTP positive as opposed to the GFP
Bright
 group where 
more than 90% were Br-UTP negative (labelled with arrow in Figure 17). In GFP
Dim
 
group, Br-UTP positive was only visible in about 30% of cell population (labelled 
with arrows in Figure 17) with the majority being Br-UTP negative. The expression 
level of GFP-MLL5 appeared to be co-relating negatively to the percentage of Br-
UTP that was being incorporated. These findings indicate that changes in MLL5 
protein level either through over-expression or siRNA-mediated knockdown 
decreased transcription activity. Collectively, given the close association between 
MLL5 and the splicing components as seen earlier, this signifies an important role of 
MLL5 in co-transcriptional splicing and prompts us to examine its relationship with 










































Figure 17: Exogenous introduction of MLL5 triggered transcription block. (Top) 
GFP-MLL5 was expressed to various extents as observed by the intensity of the green 
fluorescence in cells that were successfully transfected. (Bottom) Cells were 
categorised into three groups: Strongly expressed (GFP
Bright
), Weakly expressed 
(GFP
Dim




 group, more than 90% were Br-
UTP positive. In GFP
Bright 
group, more than 90% were Br-UTP negative (labelled 
with arrow). In GFP
Dim
 group, Br-UTP positive was only visible in about 30% of cell 





3.8 Association of MLL5 and RNAPII 
 
To begin with, we examined whether MLL5 exhibited a co-localization pattern with 
RNAPII by immunofluorescence staining. As shown in Figure 18, unlike the distinct 
speckle-like staining pattern of MLL5, RNAPII showed a characteristic granular 
distribution, most probably due to its organisation into transcription factories that 
harboured enzymes for RNA synthesis (Cook, 1999).  
 
Figure 18: Distribution pattern of MLL5 and RNAPII. Unlike the distinct 
punctate staining of MLL5 speckles, staining pattern of RNAPII using the respective 
antibodies was generally observed to be distributed uniformly throughout the cell 
nucleus. CTD4H8 recognised both phosphorylated and unphosphorylated RNAPII, 
H14 recognised phosphor-serine 5 of RNAPII while H5 recognised phosphor-serine 2 
of RNAPII. There seemed to be a certain degree of co-localization between MLL5 






To further assessed the possible interaction between MLL5 and RNAPII, FLAG-
MLL5 was over-expressed in 293T cells and the cell lysates were immunoprecipitated 
by anti-FLAG antibody and probed with various RNAPII antibodies. RNAPII has two 
physiologically important phosphorylation sites; Serine-5 and Serine-2 in the 
heptapeptide repeats (YSPTSPS) at RNAPII CTD. CTD4H8 antibody recognizes both 
the phosphorylated and non-phosphorylated form of RNAPII, H14 recognizes 
phosphor-Serine 5 while H5 recognizes phosphor-Serine 2. As shown in Figure 19, 
FLAG-MLL5 was able to co-immunoprecipitate with both phosphorylated forms of 
RNAPII, as detected by H5 and H14 antibodies. RNAPII phosphor-Serine 2 is 
involved in transcription elongation where phosphorylation is catalysed by P-TEFb 
complex comprising Cdk9-Cyclin T subunits. Previous finding reported Cyclin T1 to 
be enriched to a greater extent within the nuclear speckles as compared to its 
interacting kinase, Cdk9 and it functions to recruit other binding partners to the 
nuclear speckles  (Herrmann and Mancini, 2001). Interestingly, we found that MLL5 
co-immunoprecipitated Cyclin T1 but not Cdk9. The failure in detecting Cdk9 in 
MLL5 eluate was possibly due to the portion of Cyclin T1 that existed free of Cdk9 as 
the latter has been reported to be present in several other complexes that do not 
contain Cyclin T1 (Kass et al., 1997; Peng et al., 1998). Another interesting 
observation was that the band of Cyclin T1 in the FLAG-MLL5 eluate appeared to be 
migrating at a slower rate as compared to the band of Cyclin T1 in the input. It is of 
interest to determine the slower migrating band of Cyclin T1. Nonetheless, we 
speculate that MLL5 could tether to the transcriptional machinery and may participate 









Figure 19: Association of MLL5 and RNAPII. Immunoprecipitation study showed 
that MLL5 associates with both phosphorylated forms of RNAPII. CTD4H8 
recognised both forms of RNAPII, H14 recognised phosphor-serine 5 of RNAPII and 
H5 recognised phosphor-serine 2 of RNAPII. Interestingly, MLL5 co-
immunoprecipitated Cyclin T1 but not Cdk9, possibly due to the portion of Cyclin 
T11 that existed free of Cdk9. Also, the band of Cyclin T1 in the FLAG-MLL5 eluate 





3.9 MLL5 overexpression resulted in a slower migration of Cyclin T1 
 
It is noted that the Cyclin T1 protein present in the FLAG-MLL5 eluate (Figure 19) 
appeared to migrate slower as compared to the input lysate.  It has been reported that 
when cells were treated with transcriptional inhibitors, splicing activity was reduced 
and the nuclear speckles labelled with anti-SC35 antibody were observed to be fewer 
in number, enlarged and rounded  (O'Keefe et al., 1994). In addition, Herrmann et al 
(Herrmann and Mancini, 2001) reported that apart from Cdk9, Cyclin T1 was also 
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found to coalesce  into enlarged speckles that coincided with SC35 labelling when 
cells were treated with transcription inhibitors, Actinomycin D or DRB. We thus 
speculate that the slower migrating band of Cyclin T1 could be a result of 
transcription inhibition. To test this, we carried out immunoprecipitation and probed 
for Cyclin T1 in two different settings. In the first setting, HeLa cells were treated 
with transcription inhibitor, DRB, for 3 h before the cells were harvested and 
immunoprecipitated by anti-MLL5-8009 antibody. In the second setting, we 
transfected FLAG-MLL5 into 293T cells for 48 h before the cells were harvested and 
immunoprecipitated by anti-Cyclin T1 antibody. Interestingly, as shown in Figure 20, 
the slower migrating band of Cyclin T1 was not observed in DRB treated cells. 
Instead, it was observed in cells that were transfected with FLAG-MLL5. This 
suggested that the slower migration was not attributed solely to transcription 
inhibition, but more likely due to post-translational modifications such as acetylation 
or phosphorylation that could have occurred on Cyclin T1 in the event of transcription 
inhibition and triggered by the over-expression of MLL5 through an unknown 
mechanism. Alternatively, this observation suggested that MLL5 could have a higher 
binding affinity towards the modified form of Cyclin T1. This observation certainly 









Figure 20: MLL5 overexpression resulted in a slower migration of Cyclin T1.  
HeLa cells were treated with transcription inhibitor, DRB, for 3 h before the cells 
were harvested and immunoprecipitated (IP) by anti-MLL5-8009 antibody. In the 
parallel experiment, FLAG-MLL5 was transfected into 293T cells for 48 h before the 
cells were harvested and IP by anti-Cyclin T1 antibody. Interestingly, the slower 
migrating band of Cyclin T1 was not observed in DRB treated cells but in cells that 




3.10 MLL5 knockdown does not affect the phosphorylation state of RNAPII 
 
Since the phosphorylation state of RNAPII co-relates with the transcription status of 
the cell, we would like to examine if the transcription block induced by knockdown of 
MLL5 could alter the phosphorylation status of RNAPII. α-amanitin, a known 
transcription inhibitor that affects the general level of phosphorylated RNAPII, is used 
as a positive control (Lindell et al., 1970). Following exposure of U2OS cells to NC-
siRNA, MLL5-siRNA (#1 or #2+#3) for 72 h, cells were harvested and the 
phosphorylation level of RNAPII was visualised by Western blotting using phosphor-
epitope specific antibodies. Immuno-blotting analysis in Figure 21 showed that the 
phosphorylation states of RNAPII remained largely unaffected in comparison to α-
amanitin-treated cells which resulted in a decrease in both the phosphorylated forms. 
This observation implied that MLL5-induced transcriptional inhibition might not 
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affect the initiation or elongation process in a conventional way but occurred by other 
yet to defined mechanisms. Since it is known that the chromatin structure may 
regulate the transcription activity (Paranjape et al., 1994), we speculate that MLL5-
siRNA treated cells may cause chromatin modifications, leading to the reduction in 
the transcription activity of RNAPII.  
 
Figure 21: MLL5 knockdown does not affect the phosphorylation state of 
RNAPII. MLL5-siRNA #1 or MLL5-siRNA #2+#3 treated samples did not show a 
significant change in the phosphorylation state of RNAPII as opposed to α-amanitin-
treated control samples. The transcription inhibitor, α-amanitin, is known to decrease 
the total level of RNAPII (8WG16) and phosphor signals for both Serine-5 (H14) and 













3.11 MLL5 knockdown affects chromatin structure  
 
Cellular levels of histone signatures, mainly histone methylation or acetylation, were 
examined in cultured cell lines transfected with scrambled siRNA or MLL5-siRNA  
(#1 or #2+#3) for 72 h before the cell lysates were harvested for analysis of the 
chromatin. Antibodies specific to mono-, di and tri-methylated H3K4, H4 acetylation 
and H3K9 tri-methylation were used. As shown in Figure 22, H3K4 tri-methylation 
and histone H4 acetylation chromatin markers were dramatically reduced upon MLL5 
knockdown. Less effect was seen for H3K4 di-methylation and no changes in the 
expression of H3K4 mono-methylation and H3K9 tri-methylation was detected. As 
such, we speculate that the global chromatin structure would be affected in MLL5-
siRNA (#1 or #2+#3) treated cells. To address this, micrococcal nuclease (MNase) 
accessibility assays was conducted. Briefly, cells were treated with MLL5 siRNA #1 
or MLL5 siRNA #2+#3 for 72 h before the cells were permeabilized with lysolecithin 
and treated with increasing amounts of MNase (0, 6.25, 12.5, 25, 50 and 100 Units) 
before comparing the MNase cleavage pattern between the NC-siRNA treated cells 
and MLL5-depleted samples. As seen in Figure 23, we observed a significant 
decrease in the MNase sensitivity in MLL5-siRNA (#1 or #2+#3) treated cells as 
compared to NC-siRNA treated cells. More units of the MNase enzyme were required 
to cleave the same amount of DNA and this was likely due to the global chromatin 
structure being more compacted and hence less accessible to MNase. This observation 
is consistent with the histone modifications described above and support the notion 
that MLL5-depleted cells has a widespread influence on chromatin structure, resulting 





Figure 22: Analysis of chromatin modifications in MLL5 knockdown cells. 
Cultured cell lines were transfected with scrambled siRNA or MLL5-siRNA (#1 or 
#2+#3) for 72 h before the cell lysates were harvested and the cellular levels of 
histone signatures were probed in MLL5-depleted cell lysates.  Antibodies specific to 
mono-, di and tri-methylated H3K4, H4 acetylation and H3K9 tri-methylation were 
used. Transcriptional markers for gene activation, H3K4 tri-methylation and histone 
H4 acetylation, were seen to largely decrease upon MLL5 knockdown in all the three 









Figure 23: Analysis of chromatin organization in MLL5 knockdown cells. 
(Bottom) Concentration-dependent MNase assay (0, 6.25, 12.5, 25, 50 and 100 Units 
of MNase) was performed to analyse the changes on the global chromatin folding. 
MLL5-depletion rendered the in vivo chromatin to be less accessible to micrococcal 




3.12 MLL5 and chromatin remodelling complex  
 
Mammalian SWItch/Sucrose Non Fermentable (SWI/SNF) complex comprises of at 
least nine subunits, including one of the two alternative ATPase subunits, Brm or 
Brg1 that provides the source of energy for chromatin remodelling. To further 
understand how MLL5 could have affected the chromatin organization, we asked if 
MLL5 could also be associated with proteins implicated in chromatin remodelling 
such as the SWI/SNF-related chromatin-remodelling complex. U2OS cells were 
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treated with MLL5 siRNA (#1 or #2+#3) for 72 h before cell lysates were harvested 
for examining the expression profiles of the SWI/SNF subunits including Brm, Brg1 
and Brm/Brg1 associated factor (Baf) - Baf155. As shown in Figure 24, MLL5 
depletion resulted in a concomitant decrease in the expression levels of Brm and 
Baf155. Even though the functional consequences of the depletion in the SWI/SNF 
subunits remains elusive, this preliminary result further supports the notion that 
MLL5 participates in transcription regulation through its effects on the chromatin 
structure, as revealed by alterations in histone modifications and the expression level 
of chromatin remodelling subunits. In addition, it would also be interesting to 
determine if MLL5 regulates Brm and Baf155 at the transcriptional level.      
 
 
Figure 24: Effect of MLL5 knockdown on SWI/SNF protein complex. U2OS cells 
were treated with MLL5 siRNA (#1 or #2+#3) for 72 h before the cells were 
harvested and probed for the proteins with the indicated antibodies. SWI/SNF, a 
chromatin remodelling complex, contains either Brg1 or Brm as the ATPase catalytic 
core subunit and a set of Brg1/Brm-associated factors (BAF). MLL5 knockdown 
caused a decrease in Brm and BAF155.  
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3.13 MLL5 and splicing activity 
 
There is significant evidence to support the notion that transcriptional elongation and 
pre-mRNA splicing are linked within the cell either temporarily, spatially or 
functionally (Rain et al., 1998; Orphanides and Reinberg, 2002). Therefore, it is 
rational to speculate that the splicing activity may reduce upon knockdown of MLL5. 
A double-reporter splicing assay designed by Nasim and colleagues was employed to 
carry out the study (Nasim et al., 2002). pTN23 plasmid was a kind gift from M. T. 
Nasim and I. C. Eperon (University of Leicester, Leicester, United Kingdom). pTN23 
plasmid contained a target intron introduced between two reporters, β-galactosidase 
luciferase. The upstream β-galactosidase reporter is expressed regardless of splicing. 
Upon splicing, the internal translation termination signal is removed and this causes 
the upstream β-galactosidase reporter to be in-frame with the downstream luciferase 
reporter. The downstream luciferase reporter is expressed after splicing and the ratio 
of luciferase activity to β-galactosidase activity is dependent on the proportion of 
transcripts that are spliced. The principle of this splicing assay is illustrated in Figure 
25.  
 
Briefly, 293T cells were first knockdown with MLL5-siRNA (#1 or #2+#3) and 
SC35- siRNA #1+#2 for 24 h before pTN23 plasmid was introduced. After 48 h, cells 
were treated again with the respective siRNA to ensure that MLL5 level remained 
minimal at the point of harvest at 96 h. As seen from the Western blotting results in 
Figure 26, the knockdown efficiency for all siRNA were relatively efficient. MLL5-
siRNA (#1 or #2+#3) treated cells displayed a modest decrease in the splicing activity 
as revealed by an accumulation of the un-spliced transcripts. Luciferase assay was 
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also conducted and a similar trend of a decrease in splicing activity was observed and 
the significance is reflected by the p-value. The reduced level was comparable to that 
of SC35-siRNA treated cells. This data further supports the importance of maintaining 
a basal level of MLL5. The alteration in MLL5 level can trigger a cascade of cellular 
events that include an impediment to transcription and splicing processes.  
 
Figure 25: A test system for determining the splicing efficiency in mammalian 
cells. The splicing efficiency assay system is based on the reporter genes that encode 
for β-galactosidase (β – gal) and Luciferase (Luc). These reporter genes are fused in-
frame through recombinant fragments of the genes encoding adenovirus (Ad) and the 
skeletal muscle isoform (SK) of human tropomyosin. The recombinant fragment 
contains three in-frame translation stop signals (XXX) in the intronic region. Upon 
transfection into the mammalian cells, the pre-mRNA can be processed in either one 
of the ways. Firstly, with inefficient splicing, the RNA produced contains premature 
termination codons, resulting in β-galactosidase activity. Secondly, if there is efficient 
splicing, the translation stop signals are removed and this leads to the production of a 
fusion protein, generating both β-galactosidase and luciferase activity. [Adapted from 








Figure 26: Analysis of splicing efficiency in MLL5 knockdown cells. pTN23 
plasmid was co-transfected in MLL5-depleted cells. RNA was prepared and the 
amplification products were resolved in 2% agarose gel. Splicing products are shown 
on the right-hand side. Cell lysates was prepared to check for the knockdown 
efficiency. MLL5 knockdown cells showed a decrease in splicing efficiency.  
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CHAPTER 4 – DISCUSSION 
 
4.1 An overview 
 
In this study, we demonstrated that MLL5 co-localized and physically interacted with 
splicing factor SC35. A change in MLL5 protein level either by ectopic over-
expression or siRNAs-mediated knockdown resulted in enlarged SC35 speckles that 
are known to correlate with defects in co-transcriptional splicing. We showed that 
MLL5 is sensitive to the transcription state of the cell and associates with the 
transcription machinery. Perturbation in MLL5 expression level affects global 
transcription activity through histone modifications and chromatin remodelling. Here, 
we documented for the first time the functional importance of maintaining MLL5 
homeostasis as disruptions to MLL5 expression level can consequently lead to 
deregulation of transcription and splicing processes.  
 
4.2 Importance of maintaining MLL5 at a homeostatic level  
 
The regulation of gene expression in multi-cellular organisms forms the basis of cell-
type specificity and aberrantly expressed genes have profound effects on cellular 
functions and underscore the onset of many diseases. The transcription of protein-
coding genes in eukaryotes is governed by RNAPII. As shown in Figure 27 (Top), the 
synthesis of nascent transcripts by RNAPII involves multiple processes that occur 
either sequentially or in parallel. The C-terminal domain of the large subunit of 
RNAPII (RNAPII CTD) is sequentially and extensively phosphorylated and de-
phosphorylated during different stages of transcription. During active transcription, 
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formation of an open complex between RNAPII and the DNA template allows for 
continuous progression and is a prerequisite for transcription initiation. During 
transcription initiation, Serine 5 residue of the RNAPII CTD gets phosphorylated by 
TFIIH, a protein complex that constitutes Cdk7 and Cyclin H. As RNAPII enters into 
the transcription elongation phase, Serine 2 residue of the RNAPII CTD gets 
phosphorylated by P-TEFb, a protein complex that constitutes Cdk9 and Cyclin T. It 
is noteworthy to know that even though Cdk9 has been shown to associate with three 
related members of the Cyclin T family, T1, T2a and T2b (Peng et al., 1998; Wei et 
al., 1998), Cyclin T1 is the predominant Cdk9 associated regulatory cyclin being 
examined to date. Therefore, Cdk9-Cyclin T1 subunits will be highlighted in our 
study. Apart from the Cyclin T family, Cdk9 has also been found to bind to cyclin K. 
However, the function of Cdk9-Cyclin K is less clear (Yu and Cortez, 2011). Recent 
findings suggest Cdk9-Cyclin K to be involved directly in the maintenance of the 
genome integrity. Moreover, the depletion of Cdk9 or its Cyclin K but not Cyclin T 
regulatory subunit not only impairs cell cycle recovery in response to replication 
stress, but also induces spontaneous DNA damage in replicating cells. CDK9-Cyclin 
K also interacts with ATR and other DNA damage response and DNA repair proteins 
(Yu et al., 2010). However, the underlying mechanisms for these still remain elusive.  
 
The RNAPII CTD physically interacts with a large number of proteins and can be 
portrayed as a “docking site” for factors required for different mRNA maturation 
events that occur concomitantly with transcript elongation. As nascent transcripts are 
generated by RNAPII, spliceosome formation occurs in parallel and this is a dynamic 
process with constant shuttling of proteins and RNA components during the splicing 
reaction (Kim et al., 2011). As such, nascent transcripts can be simultaneously 
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assembled into splicing complexes and undergo splicing. In this study, we have 
identified MLL5 as a novel protein that not only associated with the phosphorylated 
RNAPII CTD, but also with the serine/arginine-rich (SR) spliceosome protein family, 
splicing factor SC35. Therefore, residing in this region brings MLL5 into close 
proximity with the transcription and pre-mRNA processing machineries, thereby 
facilitating its assembly and recruitment to the transcription active sites to regulate 
gene expressions. Since the splicing factor SC35 has been reported to have an active 
role in transcription elongation (Milne et al., 2005; Caslini et al., 2009), we propose 
that MLL5 can function as a mediator for co-transcriptional splicing by utilising its 
association with the elongating RNAPII and SC35 to assist in the recognition and 
splicing of the newly synthesized mRNA.   
 
In human, CA150 (150kDa) has been reported to localize in nuclear speckles and 
interacts with both transcription elongating RNAPII, phospho-CTD RNAPII and 
splicing factors, SF1 (Goldstrohm et al., 2001). CA150 has been suggested to play a 
role in coupling transcription and splicing in vivo through the following two 
mechanisms – (1) Modification of the activity of protein-kinase complex that interacts 
with RNAPII; (2) Mediation of the recruitment of other effectors to the elongation 
complex (Goldstrohm et al., 2001; Sanchez-Alvarez et al., 2006). More work is 
needed in order to underlie the detailed molecular mechanism on how MLL5 
participates in regulating the co-transcriptional splicing event. In addition, it is also 
crucial to identify other mediators that could have assisted MLL5 in the cross-talk 




The alteration of nuclear speckle morphology appears mostly dependent on MLL5 as 
inferred from the results obtained upon changing the level of MLL5. This is illustrated 
in the model in Figure 27 (Bottom). From our results, such alteration in MLL5 
expression level remarkably reduced transcription activity through multiple ways. 
Histone signatures signifying active transcription, H3K4 tri-methylation and H4 
acetylation, were significantly decreased and the chromatin became more compact. 
Even though the phosphorylation states of RNAPII remained unaffected, the closed 
complex between RNAPII and DNA template as a result of chromatin compaction 
impeded the progression of RNAPII. As such, no nascent RNA could be generated 
and this was revealed by the abrogation of Br-UTP incorporation. Besides, an 
accumulation of un-spliced transcripts through splicing assay was also observed, 
indicating a decrease in splicing activity. Based on these findings, we suggest that 
MLL5 could function as a gatekeeper in ensuring a smooth shuttling of the splicing 
factors and other accessory proteins between the various cellular compartments, in 
particular, the perichromatin fibrils and interchromatin granule clusters, to execute 
their functions in co-transcriptional splicing. Hence, in cells with altered level of 
MLL5, such trafficking is disrupted and this consequently led to a temporal 
aggregation of complexes which appeared as an enlarged-speckle phenotype, which 
has been associated with a disruption in transcription (Bregman et al., 1995) or 
splicing processes (O'Keefe et al., 1994). 
 
Cdk9/Cyclin T1 complex, also known as positive transcription elongation factor b (P-
TEFb), phosphorylates RNAPII CTD and this phosphorylation indicates the transition 
from transcription initiation to elongation. In the review by Cho et al (Cho et al., 
2010), it has been suggested that post-translational modifications on the subunits of 
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the P-TEFb complex established a new link between modifications at the RNAPII 
complex, chromatin and the regulation of transcription elongation. These 
modifications include phosphorylation, ubiquitination, and acetylation. In fact, while 
phosphorylation and ubiquitination are common modifications shared with other 
Cdk/cyclin complexes, acetylation was first identified in Cdk9 and Cyclin T1. The 
slow migrating band of Cyclin T1 observed in Figure 20 could be a result of one of 
these modifications. We speculate that the altered levels of MLL5 could trigger a 
cascade of signaling process, which consequently led to post-translational 
modifications on Cyclin T1. This is highly probably as four acetylation sites (K380, 
K386, K390 and K404) have been identified in Cyclin T1. These sites are located in 
the highly structured predicted coiled-coil region of the Cyclin T1 and acetylation on 
these sites have been reported to negatively influence the binding properties between 
P-TEFb and 7SK small nuclear RNA (snRNA). Although the exact mechanisms on 
how acetylation disrupted the 7SK snRNA ribonucleoproteins complex and liberated 
P-TEFb remained unclear, it is striking that acetylated residues occur in those 
positions of the predicted coiled-coil structure are well positioned for protein-protein 
interactions (Cho et al., 2009). In the context of our study, future studies include 
determining the significance of MLL5 having a higher affinity towards the modified 
form of Cyclin T1. Perhaps, such modifications could be a critical tethering factor for 
MLL5 to associate with RNAPII during transcription elongation. Given the 
importance P-TEFb has towards the transcriptional activity of the cell, MLL5 could 
have a synergistic role with this complex and may play a crucial role in the global 
regulation during the transcription process. Therefore, unraveling the cause of the 
slow migrating band of Cyclin T1 due to changes in MLL5 level will certainly bring 
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important clues to the cross-talk between distinct protein modifications and the role of 








Figure 27: A model illustrating the participation of MLL5 in transcription and 
splicing processes. (Top) In cells with basal level of MLL5, MLL5 interacts with the 
SR family proteins such as splicing factor SC35. P-TEFb complex phosphorylates at 
Serine-2 in the heptapeptide chain of the CTD while TFIIH phosphorylates at Serine-
5. Br-UTP is incorporated into nascent RNA as it is being synthesized by the 
spliceosome. H3K4 trimethylation and H4 acetylation denote transcription activation 
markers. Arrow indicates the direction of RNAPII moving along the transcription 
template. (Bottom) In cells with altered level of MLL5, MLL5 colluded into the 
enlarged speckle as denoted by the boundary together with other components, 
RNAPII and spliceosome. H3K4 trimethylation and H4 acetylation markers decrease 
and chromatin compaction occurs. This temporarily ceases the advancement of 
RNAPII along the transcription template. As a consequence, RNA synthesis is halted 
and Br-UTP incorporation is abrogated. See text for details. 
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4.3 Plausible roles of MLL5 transcription regulation 
 
4.3.1 MLL5 and its involvement in histone modifications 
 
Trithorax protein family, in combination with other protein complexes, exert 
chromatin remodelling and histone-modifying activities that dictate cell fate and are 
indispensable for proliferation, development or differentiation (Schraets et al., 2003). 
Studies have demonstrated that MLL family contain diverse functional domains and 
global analysis of H3K4 methylation defines MLL family member targets.  
 
MLL1 has been the most extensive studied member and participates in a large Set1 
complex that acts to maintain transcriptional activation states of target genes 
(Nakamura et al., 2002). It has been reported that Wdr82, a specific component of 
Human Set1/COMPASS, regulates H3K4 tri-methylation (Wu et al., 2008). RNA 
interference-mediated knockdown of Wdr82 resulted in a global reduction in H3K4 
tri-methylation levels, with little to no effect on H3K4 mono- or di-methylation levels. 
The group suggested that the loss of Wdr82 could possibly affect the stability of the 
entire Set1A complex, a H3K4 methylase. Another histone modification that has been 
suggested to be strongly correlating with transcription activation in a wide variety of 
eukaryotic systems apart from H3K4 methylation (particularly, the tri-methylated 
state), is histone acetylation (Strahl et al., 1999; Santos-Rosa et al., 2003). In the study 
by Dou and colleagues, the group purified a stable complex (MLL1-WDR5) 
containing both MLL1 and the MYST family histone acetyltransferase MOF. This 
MLL1 complex was found to have MLL1-mediated histone methyltransferase activity 
that can affect mono-, di- and tri-methylation of H3K4 and a MOF-mediated histone 
106 
 
acetyltransferase activity that is specific for H4K16. MOF remodelled chromatin by 
histone acetylation and charge neutralization (Dou et al., 2005). The MLL1-MOF 
complex coordinately activated transcription of MLL1 target gene, HOXA9 gene 
expression in vitro. The knockdown of MOF caused a dramatic reduction of histone 
H4K16 acetylation which consequently down-regulated HOXA9 gene expression but 
not H3K4 methylation (Dou et al., 2005; Taipale et al., 2005). This indicated that 
H4K16 acetylation by MOF is dependent upon MLL1 but H3K4 methylation by 
MLL1 can occur independently of MOF. Nonetheless, both H3K4 methylation and 
H4K16 acetyltransferase activities were required for the optimal transcription 
activation of the MLL1 target HOXA9 gene. 
 
Similar to Wdr82 and MLL1-MOF complex, our results in Figure 22 showed different 
combinations of histone modifications that dictated the transcriptional responses and 
cellular functions upon changing MLL5 level .Whether these transcription activation 
markers stems from the intrinsic enzymatic activity of MLL5 remains to be delineated.  
It would thus be intriguing to investigate if MLL5 is a component of any histone 
modifying enzyme complex and this could be done using proteomic approaches or 
through mass spectrometry. Unravelling the putative MLL5-associated complexes 
would certainly aid in better understanding of how MLL5 regulate the transcription of 
its target genes. Nonetheless, in the work described by Sebastian and colleagues 
(Sebastian et al., 2009), MLL5 indirectly regulated H3K4 methylation by regulating 






4.3.2 MLL5 and its involvement in chromatin organisation 
  
A condensation of the general chromatin structure in MLL5-siRNA treated cells 
prompted us to understand how MLL5 could exhibit such chromatin organisation 
ability. We speculate that the disruption of MLL5 homeostasis could destabilize the 
architectural scaffold for RNAPII. This could affect the genomic transcription 
template by altering the functions of transcription factors and chromatin remodelling 
enzymes. Such transcription stress could temporarily cease the advancement of the 
elongating RNAPII along the chromatin, thus inhibiting nascent RNA generation and 
reduced splicing activity.  
 
In the work described by (Knoepfler et al., 2006), myc proto-oncogenes were required 
for the widespread maintenance of active chromatin. To address whether myc levels 
influenced chromatin structure, the group conducted similar MNase accessibility 
assays using Tet-Off Myc B (P493-6) cell system (Schuhmacher et al., 1999) in which 
Myc could be reproducibly turned off by the addition of tetracycline. Results showed 
that both the loss and gain of Myc function substantially influenced widespread 
histone modifications. Similar to MLL5, down-regulation of Myc expression led to a 
decreased in active chromatin markers and DNA accessibility. It has been proposed 
that Myc may influence the global chromatin structure directly through the 
widespread binding of Myc to genomic DNA coupled with the recruitment of 
chromatin-modifying proteins; or indirectly through the up-regulation of the histone 
acetyltransferase GCN5. Since MLL5 does not have DNA binding motifs, we 
speculate that MLL5 exert its chromatin re-modification properties through an 
108 
 
indirect mechanism, such as by forming a bridging complex with the chromatin-
modifying proteins.    
 
In the case of human transcriptional co-activator PC4, PC4-mediated chromatin 
condensation lies in the direct interaction with the core histones H3 and H2B where it 
functions to link the different widely separated nucleosomes. Hence, unlike MLL5 
and Myc, silencing of PC4 resulted in chromatin de-compaction as evidenced by the 
increase in MNase accessibility (Das et al., 2006). Therefore, to unravel the 
biochemical mechanisms of MLL5 mediated transcriptional regulation on a global 
scale, future studies include defining the functional correlation of MLL5 with the 
histones, non-histone chromatin proteins (such as HP1, HMGs, and PARP-1) as well 
as chromatin modifying proteins (such as SWI/SNF complex). Even though 
preliminary study indicates that MLL5 depletion results in a concomitant decrease in 
Brm but not Brg1, the consequences of this decrease with respect to MLL5’s role in 
chromatin remodelling remains elusive. Study by Batsche and colleagues (Batsche et 
al., 2006) showed that Brm is a regulator of alternative splicing of several genes 
which include including E-cadherin, BIM, cyclin D1 and CD44. Brm also associates 
with several components of the spliceosome. To a certain extent, Brm is responsible 
for the crosstalk between transcription and RNA processing by decreasing RNAPII 
elongation rate and facilitating the recruitment of the splicing machinery to variant 
exons with suboptimal splice sites. Therefore, it would certainly be exciting to further 






CHAPTER 5 – FUTURE DIRECTION AND 
CONCLUSION 
 
5.1 Chromatin remodelling, histone modifications, and DNA methylation - How 
does it all fit together? 
 
In this study, the data presented in this report demonstrate that changes in MLL5 
expression influence transcription regulation, possibly through histone modifications 
and chromatin remodelling. Recent studies have also suggested a link between DNA 
methylation and transcription repression (Kass et al., 1997; Curradi et al., 2002; 
Flintoft, 2010). Such epigenetic modifications interfere with the binding of 
transcriptional machinery by changing recognition sites that involve cytosine, 
specifically at the CpG rich sites. CpG methylation facilitates the assembly of 
transcription repressor complexes that contain histone deacetylases, histone 
methylases and ATPase complexes that also mediate chromatin remodelling. The 
schematic diagram in Figure 28 summarizes the multiple layers of epigenetic 
modifications in the control of chromatin structure and gene expression.  In this 
regard, it would be interesting to determine if MLL5 also affects DNA methylation so 
as to further elucidate the complex interplay between these various epigenetic 
mechanisms.  
 
Recently, Heuser and colleagues reported that the treatment of homozygous Mll5 loss-
of-function mice with a DNA de-methylating agent, 5-Aza-2’-deoxycytidine, led to a 
complete loss of repopulation activity, accumulation of hematopoietic progenitors and 
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a dramatic increase of mature cells in the bone marrow (Heuser et al., 2009). The 
treatment with a histone deacetylases (HDAC) inhibitor, Trichostatin A, did not show 
similar effects, suggesting that the observations were specific for DNA demethylation. 
Therefore, it is likely that Mll5 could regulate hematopoietic differentiation and/or 
hematopoietic stem cell (HSC) renewal through yet to known mechanisms that 
involve the initiation and/or maintenance of DNA methylation. These findings 
suggest that MLL5 could be a member of the chromatin associated proteins that 
influences CpG methylation regulated gene expression and is required for the 
maintenance of methylation at critical stages of haematopoiesis.  
 
Currently, chromatin immunoprecipitation (ChIP) grade anti-MLL5 antibodies are 
unavailable, thereby inhibiting the use of direct ChIP strategies to analyze the 
promoters of target genes that could possibly be affected as result of chromatin 
modifications. Therefore, it remains a challenge to link potential target genes to post-
transcriptional regulatory programmes so as to reveal the physiological implications 





Figure 28: Possible epigenetic modifications on the chromatin. A propose model 
for how multiple epigenetic modifications can convert unmethylated, ‘‘open’’ 
chromatin into methylated, ‘‘closed’’ chromatin. Arrows indicate the possible sites of 
each epigenetic action. HP1, heterochromatin protein 1; MBD, methyl-CpG-binding 
domain protein. [Adapted from  (Geiman and Robertson, 2002) ] 
 
 
5.2 Histone modifying properties of MLL5 – When does it occur?  
 
The histone methyltransferase (HMT) activity for MLL family proteins, except MLL5, 
has been extensively studied over the years. Till date, it remains elusive if MLL5 also 
possesses such intrinsic histone methyltransferase activity. Even though it has been 
reported that MLL5 suppressed the expression of Cyclin A2 via indirect regulation of 
H3K4 methylation through LSD1 and SET7/9 in quiescent myoblasts, no histone 
methyltransferase activity was detected in recombinant MLL5 in the in vitro system 
(Sebastian et al., 2009). However, it is noteworthy to highlight that the enzymatic 
activity of MLL5 can be achieved upon specific post-translational modifications. 
During mitosis, upon being phosphorylated by CDC2, this led to the re-localization of 
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MLL5 into cytoplasm, rendering the chromatin to be inaccessible to MLL5. 
Interestingly, another group discovered that a shorter form of MLL5, MLL5α (609 
amino acids) could exert H3K4 histone methyltransferase activity only after the 
Thr440 residue of the SET domain is being GlcNAcylated (Fujiki et al., 2009). 
Therefore, it is plausible that MLL5 has to be post-translationally modified before it 
can exert its enzymatic properties. Yew and colleagues (Yew et al., 2011) also 
identified another isoform of MLL5, MLL5β (503 amino acids), that associated with 
transcription factor AP-1 at the distal region of the HPV18 long control region which 
consequently led to the activation of E6/E7 transcription. The SET domain in   
MLL5β was found to be responsible for the activation as inactivation of the SET 
domain decreased E6/E7 gene activation, though not depleting it completely. 
Nonetheless, this finding suggests that MLL5β may interact with other proteins apart 
from AP-1 to exert play a cooperative role for E6/E7 activation. In addition, other 
unidentified post-translational regulation on MLL5β could also be required for this 
activation.  
 
5.3 Cell cycle arrest or transcription inhibition – Which comes first?  
 
It has been an age-old riddle that has perplexed generations: Which came first, the 
chicken or the egg? At present, our current model also poses a scientific and 
philosophical mystery, the interesting question on the correlation between 
transcription regulation and cell cycle progression. Previous findings by our group 
have showed that either knockdown or over-expression of MLL5 caused cell cycle 
arrest at G1/S or G2/M boundaries (Cheng et al., 2008). Therefore, does transcription 
inhibition causes cell cycle arrest or cell cycle arrest causes transcription inhibition? 
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Currently, there is no evidence on which phenomenon occurs first since 
transcriptional regulation changes continuously during cell cycle progression. For 
example, when chromosomes condensed into compact structures at M-phase, most 
factors required for active gene expression are inaccessible to the binding sites on 
DNA and cells undergo global transcriptional inhibition (Kang et al., 2008). In 
proliferating cells, cell cycle-dependent transcriptional regulation occurs 
simultaneously. Hence, it remains a challenge to resolve the cell cycle mediated 




In conclusion, this study serves as a preliminary investigation for the involvement of 
MLL5 in transcription regulation. However, the detailed molecular mechanisms 
remain unclear. At present, we have demonstrated that MLL5 is a novel interacting 
partner of SC35, where the latter has recently been reported to possess bridging 
capability between transcription and splicing processes. Given the high degree of co-
localization observed between MLL5 and SC35, it is promising to investigate the 
synergistic effect of these two proteins in the co-transcriptional splicing process.  
 
Our results are also suggestive for the role of MLL5 in regulating transcription 
activity. An alteration in MLL5 level is observed to substantially influence 
transcription, possibly through a cascade of events that include histone modifications 
and chromatin remodelling. As the function of MLL5 in the context of global gene 
regulation is far from being entirely understood, a major goal for the future studies is 
to unravel the mechanisms downstream of MLL5 and identify potential in vivo 
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transcriptional targets. An attempt to elucidate if MLL5 possesses intrinsic histone 
methyltransferase activity will certainly open up a promising new direction for the 
role of MLL5 in epigenetic regulation. Investigations into this complexity will 
provide an insight into the fundamentals of gene regulation and chromatin 
organisation. This will greatly enhance the mechanistic understanding of MLL5 in 
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